ORIGINAL ARTICLE

Obesity, arterial function and arterial structure – a systematic review and meta-analysis

J. Y. A. Ne^{1,2,3}, T. Y. Cai^{1,2}, D. S. Celermajer², I. D. Caterson¹, T. Gill¹, C. M. Y. Lee¹ and M. R. Skilton¹ 💿

¹Boden Institute of Obesity, Nutrition, Exercise and Eating Disorders, University of Sydney, Australia; ²Sydney Medical School, University of Sydney, Australia; ³National University Health System, Singapore;

Received 1 November 2016; revised 23 March 2017; accepted 26 March 2017

Address for correspondence: A/Prof M Skilton, Boden Institute of Obesity, Nutrition, Exercise and Eating Disorders, D17 – Charles Perkins Centre, The University of Sydney, NSW 2006, Australia. E-mail: michael.skilton@sydney.edu.au

Summary

Objective

Obesity is an established risk factor for cardiovascular disease. The mechanisms by which obesity affects cardiovascular risk have not been fully elucidated. This paper reports a comprehensive systematic review and meta-analysis on obesity and two key aspects of vascular health using gold-standard non-invasive measures – arterial endothelial function (brachial flow-mediated dilatation) and subclinical atherosclerosis (carotid intima-media thickness).

Methods

Electronic searches for 'Obesity and flow-mediated dilatation' and 'Obesity and intimamedia thickness' were performed using Ovid Medline and Embase databases. A metaanalysis was undertaken for brachial flow-mediated dilatation and carotid intima-media thickness to obtain pooled estimates for adults with obesity and those with healthy weight.

Results

Of the 5,810 articles retrieved, 19 studies on flow-mediated dilatation and 19 studies on intima-media thickness were included. Meta-analysis demonstrated that obesity was associated with lower flow-mediated dilatation (-1.92 % [95% Cl -2.92, -0.92], P = 0.0002) and greater carotid intima-media thickness (0.07 mm [95% Cl 0.05, 0.08], P < 0.0001).

Conclusions

Obesity is associated with poorer arterial endothelial function and increased subclinical atherosclerosis, consistent with these aspects of vascular health at least partially contributing to the increased risk of cardiovascular events in adults with obesity. These estimated effect sizes will enable vascular health benefits in response to weight loss treatment to be put in greater perspective, both in the research setting and potentially also clinical practice.

Keywords: Atherosclerosis, endothelial function, meta-analysis, obesity.

Introduction

Cardiovascular events such as myocardial infarction and stroke are a major cause of morbidity and mortality (1). Atherosclerosis is the disease process that underlies the majority of cardiovascular events and is characterized by endothelial dysfunction and arterial wall thickening. The non-invasive methodologies most commonly used to assess these aspects of vascular health in research studies are brachial artery flow-mediated dilatation (FMD) and carotid intima-media thickness (IMT). Both have been used extensively to study the effects of putative risk factors on the vasculature and predict future risk of cardiovascular events (2,3).

Obesity is an important cardiovascular risk factor. A number of studies have determined the associations of obesity with markers of vascular health, albeit with mixed findings. Studies of obesity and brachial FMD have

© 2017 The Authors

Obesity Science & Practice published by John Wiley & Sons Ltd, World Obesity and The Obesity Society. Obesity Science & Practice **171** This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

shown either preserved or impaired endothelial function (4-7). In contrast, studies of carotid IMT have usually shown increased IMT in people with obesity, although with markedly different effect size estimates. Clarifying these associations has implications for the mechanisms linking obesity with cardiovascular events and will have implications for treatment strategies, particularly those that specifically seek to lower cardiovascular risk in obesity. For instance, a clear indication of the effect size of the increased carotid IMT in obesity will enable a more accurate estimation of the proportion of cardiovascular risk in obesity that is related to atherosclerotic vascular disease, and as such assist in identifying the mechanisms to target for the likely most efficacious approach to reducing risk of heart disease in people with obesity. Similarly if obesity is accompanied by lower brachial FMD, the use of strategies that improve endothelial function, independent of weight loss, may become viable to lower risk of cardiovascular events. Weight loss itself has been demonstrated to be associated with increases in brachial FMD and reductions in carotid IMT (8.9).

Nonetheless, unlike weight loss, such strategies aimed at improving vascular function *per se* would not infer benefits for other obesity-related comorbidities but may be of benefit as an addendum to weight loss or for people who are resistant to weight loss.

Accordingly, a comprehensive systematic review of the available literature on obesity and vascular health (as assessed by brachial FMD, and carotid IMT) was undertaken, with subsequent meta-analysis to determine whether these markers of vascular health differ between adults with obesity and those with healthy weight, and the estimated effect size of any such difference. Studies were restricted to those that defined obesity using body mass index (BMI), which despite being unable to differentiate between different types of obesity, is the most commonly used measure in clinical practice.

Methods

Search strategy and selection criteria

The MOOSE checklist was used as a guide to prepare this systematic review and meta-analysis. Electronic searches were performed on 29 January 2017 using Ovid Medline and Embase databases, to identify papers published through end-2016. Searches were run in each database, relating to 'Obesity and FMD' and 'Obesity and IMT'. Relevant search terms under each search category 'Obesity' (Obesity, morbid obesity, overweight, obes*, BMI, body mass index), 'Flow-mediated dilatation' (flow mediated dilat* or vasodilat*, FMD) and 'Intima media thickness' (intima media thickness, IMT) were identified and used.

To maximize sensitivity of the search, relevant terms were combined as keywords or subject heading (MeSH) terms within each category. After the initial screening of titles and abstracts, the full text of potentially relevant articles were obtained and evaluated. To further identify relevant studies, a secondary search was also carried out by reviewing the reference lists of all shortlisted articles.

Inclusion criteria

To ensure consistency, only studies that used BMI to define obesity and studies which measured brachial FMD and common carotid IMT as endpoints were included. Studies were included if participants were categorized on the basis of study-specific BMI cutpoints, into those with some degree of obesity and those with healthy weight. A sensitivity analysis was undertaken in studies using World Health Organization criteria (Controls <25 kg m⁻², Obesity ≥30 kg m⁻²). The limits 'humans' and 'adults ≥18 years old' were added to make the searches more specific. Date limits were applied according to when the FMD and IMT techniques were first described (1992 and 1984, respectively). No language limits were applied.

Exclusion criteria

The following types of studies were excluded: Studies in which the participants with obesity all had a specific comorbidity, studies without a healthy weight comparator, studies which did not assess FMD and IMT as endpoints and studies from which the mean, standard deviations or standard error were unable to be extracted or converted. For studies in which the group with obesity was stratified into two groups (with and without a specific comorbidity), the group with the specific co-morbidity was excluded. As obesity is associated with an increased risk of metabolic co-morbidities, studies that included participants with metabolic risk factors, but did not specifically select based on these risk factors, were not excluded. Abstracts, case reports, conference presentations, editorials and expert opinions were excluded.

Screening of articles, data extraction and critical appraisal

All 5,810 titles, relevant abstracts and relevant full-text articles from the primary and secondary search were

screened by the main reviewer (J.Y.A.N). All titles and relevant abstracts from the primary search were also independently screened by a second reviewer (T.Y.C). Discrepancies were resolved by discussion and consensus. Relevant data were extracted from the articles, tables and figures by the main reviewer.

Statistical analysis

The sample size, mean and SD of relevant data (age, BMI, FMD and IMT) from the group with obesity and the control group were extracted from each study. For studies with measures of both mean and maximum carotid IMT, or a composite measure derived from multiple areas of the carotid tree, the measure of mean common carotid IMT was used preferentially in analysis. To determine the net effect of obesity on vascular health, a meta-analysis was performed by combining the mean difference of FMD or IMT between the adults with obesity and those with healthy weight from the different studies to obtain pooled estimates. Weighted mean and pooled variance were used when the group with obesity or the control group were stratified into two groups according to age, type of obesity or amount of inflammatory markers (e.g. high sensitivity C-reactive protein). The random effects model was used to account for the variation in baseline characteristics of different populations as well as the methodological variation among the different studies. An I² value of greater than 50% indicated substantial heterogeneity. Possible causes of substantial heterogeneity, specifically age, sex, BMI cut-points for healthy weight and obesity, measurement methodology (for IMT only) and site of occlusion (for FMD only), were explored by conducting sensitivity analyses stratified by subgroup. Statistical significance was inferred at P < 0.05. Statistical analysis was undertaken with Review Manager Version 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark).

Results

Search results – brachial flow-mediated dilatation (FMD)

A total of 1,611 references were identified through the two electronic database searches in the primary search. A secondary search of references from shortlisted articles from the primary search yielded an additional 944 articles. After removal of duplicates, 1,994 references remained for screening, of which 1,811 were excluded because they did not meet the inclusion criteria. The remaining 183 full-text articles were assessed for eligibility. After screening these articles based on the selection criteria, 19 studies remained for analysis.

Nineteen of these FMD studies are cross-sectional studies of adults with obesity and controls. In these studies, a total of 2,733 participants were compared, including 1,680 controls and 1,053 adults with obesity. A summary of characteristics of the study populations is presented in Table 1.

Search results – carotid intima-media thickness (IMT)

A total of 4,081 references were identified through the two electronic database searches in the primary search. A secondary search of references from shortlisted articles from the primary search yielded an additional 1,064 articles. After removal of duplicates, 3,901 references remained for screening, of which 3,760 were excluded because they did not meet the inclusion criteria. The remaining 141 full-text articles were assessed for eligibility. After screening these articles based on the selection criteria, 19 studies remained for analysis.

Of the 19 studies included in the meta-analysis, 14 of them are cross-sectional studies, and 5 of them are longitudinal studies. In these studies, a total of 9,821 participants were compared, including 4,999 controls and 4,822 adults with obesity. A summary of characteristics of the study populations is presented in Table 2.

Meta-analysis results – brachial FMD and carotid IMT

The meta-analysis showed potentially meaningful and statistically significant differences in brachial FMD and carotid IMT between the adults with obesity and those who are healthy weight, with the adults with obesity having lower FMD (-1.92 % [95% CI: -2.92, -0.92], P = 0.0002, n = 1,053; Figure 1) and higher carotid IMT (0.07 mm [95% CI: 0.05, 0.08], P < 0.0001, n = 4,822;Figure 2) than the healthy weight adults (n = 1,680[FMD], n = 4,999 [IMT]). However, there was significant heterogeneity, based on I^2 test (I^2 > 50%). The association of obesity with lower brachial FMD and greater carotid IMT did not differ by age or sex (Figures 3, 4, 7 and 8), with the estimated mean differences being profoundly similar between all subgroups. Similar results were found in studies that used standard World Health Organization criteria for obesity and healthy weight, and studies that used alternative criteria (Figures 5 and 9). Heterogeneity between studies remained high in these

© 2017 The Authors

			Mean age (year)		Gender (% males)	males)	BMI cut-off (kg m $^{-2}$)	$kg m^{-2}$	Mean BMI (kg ${ m m^{-2}}$)	
Author	Year	Study design	Controls	Obesity	Controls	Obesity	Controls	Obesity	Controls	Obesity
Hashimoto (16)	1998	Cross-sectional	37.3 ± 1.9	S:37.9 ± 4.1 [*]	100	100	<26	≥26	22.5 ± 0.4*	S:30.4 ± 1.1 [°] ,
				$V:37.5 \pm 1.5^{*}$						$V:29.7 \pm 0.5^{*}$
Oflaz (7)	2003	Cross-sectional	30.6 ± 7.2	31.4 ± 7.5	0	0	<24	>30	20.4 ± 1.6	34.2 ± 3.8
Yu (26)	2003	Cross-sectional	33.4 ± 12.3	34.1 ± 12.2	100	100	<24	>28	21.9 ± 1.9	32.8 ± 4.1
Pulerwitz (27)	2006	Cross-sectional	$65.2 \pm 8.0^{\ddagger}$	ь 8.0 [‡]	41.7		<25	>30		28.0 ± 4.6 [‡]
Olson (28)	2006	Cross-sectional	$34.0 \pm 2.0^{*}$	$37.0 \pm 1.0^{*}$	0	0	18.0–24.9	30.0-34.9	$22.0 \pm 0.5^{*}$	$31.8 \pm 0.4^*$
Zhu (14)	2007	Cross-sectional	45.3 ± 5.3	44.2 ± 6.4	62.8	63.7	<25	>30	22.8 ± 1.7	28.3 ± 2.0
Mizia-Stec (29)	2008	Cross-sectional	Control A <35:	29.7 ± 6.2	0	0	Control A:	>30	Control A:	33.6 ± 2.9
			28.0 ± 7.6,				20.8–27.6;		$24.0 \pm 3.8;$	
			Control B >45:				Control B:		Control B:	
			51.9 ± 4.4				21.9–28.3		25.8 ± 2.9	
Patel (30)	2009	Cross-sectional	51 ± 1 [‡]	ь 1 [‡]	0	0	<25	>30	~	NIL
Skilton (31)	2008	Cross-sectional	$42.8 \pm 2.5^{*}$	$44.4 \pm 1.3^{*}$	27.3	20.5	<24	>30	$21.9 \pm 0.4^{*}$	44.6 ± 1.6*
Lind (32)	2009	Cross-sectional	40.0 ± 19.0	41.0 ± 11.0	26.0	26.0	NIL	NIL	23.1 ± 2.0	43.8 ± 3.1
Fahs (33)	2009	Cross-sectional	$25.7 \pm 1.2^*$	$33.8 \pm 1.3^{*}$	100	100	<25.9	≥29.5	$23.6 \pm 0.3^{*}$	$32.8 \pm 0.5^*$
Ayer (34)	2010	Cross-sectional	31.6 ± 5.3	32.1 ± 6.3	63.6	63.6	18–25	>30	22.6 (21.7–24.2) [†]	46.4 (35.4–53.6)
Biasucci (4)	2010	Cross-sectional	48.4 ± 5.6	51.0 ± 6.2	38.5	57.1	NIL	NIL	23.2 ± 1.6	32.6 ± 2.5
Zhu (35)	2010	Cross-sectional	22.4 ± 1.5	22.5 ± 0.9	100	100	NIL	NIL	20.1 ± 2.5	32.2 ± 1.7
Ayer (36)	2011	Cross-sectional	31.0 ± 5.3	32.7 ± 5.3	52.6	52.6	18–25	>30	22.4 ± 1.6	44.1 ± 9.0
Mah (37)	2011	Cross-sectional	$22.0 \pm 1.3^*$	$21.0 \pm 1.0^{*}$	100	100	18–25	27—40	$21.9 \pm 0.65^*$	35.9 ± 1.9*
Doupis (38)	2011	Cross-sectional	54.0 ± 13.0	51.0 ± 10.0	50.0	51.0	<30	>30	24.9 ± 3.4	38.1 ± 7.1
Vinet (39)	2011	Cross-sectional	48.2 ± 1.6*	$51.0 \pm 2.5^*$	100	100	<25	≥30	$24.3 \pm 0.3^{*}$	33.9 ± 1.1*
Martin (40)	2013	Cross-sectional	48.3 ± 10.4	52.2 ± 8.0	100	100	<30	>30	26.7 ± 2.0	32.9 ± 2.7
Data presented as mean ± SD except: *Mean + SF	as mean ± (SD except:								
†Median, IQR.										
[‡] Value for controls and obesity combined.	and obe	sity combined.								
 Subcutaneous opesity. V. visceral obesity. 	s opesity.									
	· · ·									

Table 1 Summary of studies included in meta-analysis of obesity and brachial FMD

Obesity Science & Practice published by John Wiley & Sons Ltd, World Obesity and The Obesity Society. Obesity Science & Practice

© 2017 The Authors

Author Year Study design Controls Obserity Controls Controls Controls Control				Mean age (year)		Gender (% males)		BMI cut-off (kg m^{-2})	kg m ^{2})	Mean BMI (kg m $^{-2}$)	m ⁻²)
	Author	Year	Study design	Controls	Obesity	Controls	Obesity	Controls	Obesity	Controls	Obesity
(42) 199 Cross-sectional intervention 29 ± 6.3 21.7 <27 (3) 2001 Baseline data from intervention 41 40 0 0 25 (4) 2002 Baseline data from properine data from properine data from $206 \pm 7/2$ 54.0 ± 0.9 $55.0 \pm 0.8^{\circ}$ 0 0 <28 (1) 2003 Cross-sectional $30.6 \pm 7/2$ 34.1 ± 12.2 100 0 <24 (1) 2003 Cross-sectional 34.8 ± 12.3 34.1 ± 12.2 100 0 <24 (3) 2003 Cross-sectional $34.8 \pm 16^{\circ}$ $34.4 \pm 13^{\circ}$ 27.3 20.5 <24 (3) 2003 Cross-sectional $44.8 \pm 16^{\circ}$ 29.7 ± 6.2 52.6 22.4 (3) 2008 Cross-sectional $44.8 \pm 16^{\circ}$ $46.5 \pm 13^{\circ}$ 0 0 0 20.5 (4) 2003 Cross-sectional $40.1 2 \pm 16.1$ 20.2 ± 5.7 <	Karason (41)	1999	Baseline data from intervention study	+1	+1	77	62	20–28	30-40	24 ± 2	37 ± 4
(4) 2001 Baseline data from survention survention 41 40 0 0 0 0 0 rele (44) 2002 Baseline data from survention 54,0±,0.5 55,0±,0.8* 0 0 0 < 25 rele (44) 2003 Baseline data from survention 54,0±,0.9* 55,0±,0.8* 0 0 0 < 24 (3) 2003 Cross-sectional 33,4±12.3 34,1±12.2 100 100 < 24 (3) 2007 Cross-sectional 36,4±,3.3 $34,4\pm1.3^{\circ}$ 27.3 20.5 < 24 (3) 2007 Cross-sectional $34,4\pm1.3^{\circ}$ 27.3 20.5 < 24 (3) 2008 Cross-sectional $34,4\pm1.6^{\circ}$ $35,4\pm1.3^{\circ}$ 100 0 < 25 (4) 2010 Cross-sectional $44,4\pm1.6^{\circ}$ $51,0\pm6.8^{\circ}$ $21,0\pm2.8^{\circ}$ $21,0\pm2.8^{\circ}$ (4) 2010 Cross-sectional $44,4\pm1.6^{\circ}$ $51,0\pm6.8^{\circ}$ $21,0\pm6.8^{\circ}$ $21,0\pm2.8^{\circ}$ $21,0\pm2.8^{\circ}$ $21,0\pm2.8^{\circ}$ $21,0\pm2.8^{\circ}$ $21,0\pm2.8^{\circ}$	Ciccone (42)	1999	Cross-sectional	28.9 + 6.3	29.2 + 8.4	38.3	41.7	<27	>27	22.7 + 2.6	35.6 + 6.8
intervention intervention $study$ (weight loss) $study$ (weight loss) $study$ (weight loss) $study$ (weight loss) $passine data train study (weight loss) study (weight loss) study (weight loss) passine data train study (weight loss) study (weight loss) study (weight loss) passine data train study (weight loss) study (weight loss) study (weight loss) passine data train 34.12.3 34.11.2.2 100 100 <24 13 2003 Cross-sectional 36.5.7.2 44.4.13^{*} 27.3 20.5 <24 (31) 2008 Cross-sectional 36.4.7.2 31.4.4.3 20.5 <24 (31) 2008 Cross-sectional 44.8.1.6^{*} 46.5.1.1^{*} 38.6.7.2.3 20.5.5.2.3.3^{*} (4) 2011 Cross-sectional 31.0.5.5.2 51.0.6.5.2.3.4 20.5.2.4^{*} 20.5.5.3.3^{*} (4) 2011 Cross-sectional 31.0.5.5.2^{*} 20.5.5.3.4^{*} 20.5.5.3.4^{*} $	Mavri (43)	2001	Baseline data from	41	40	0	0	NIL	NIL	NIL	30.6 ± 5.0
study (weight loss) study (weight loss) study (weight loss) iele (44) 2002 Baseline data from 54.0 ± 0.9" 55.0 ± 0.8" 0 0 < 25 (1) 2003 Cross-sectional 33.4 ± 12.3 3.4.1 ± 12.2 100 100 < 24 (1) 2003 Cross-sectional 30.6 ± 7.2 31.4 ± 1.3 27.3 0 0 < 24 (31) 2003 Cross-sectional 30.6 ± 7.2 31.4 ± 1.3' 27.3 20.5 < 24 (31) 2008 Cross-sectional 34.4 ± 3.3' 20.7 0 0 < 25 (31) 2008 Cross-sectional 34.4 ± 3.3' 20.7 0 0 20.4 (31) 2008 Cross-sectional 44.4 ± 1.3' 27.3 20.5 < 24 (31) 2008 Cross-sectional 44.4 ± 1.3' 27.3 0 0 < 25 (31) 2008 Cross-sectional 44.4 ± 1.3' 45.5 ± 1.0' 10.0' < 25 (31) 2008 Cross-sectional 26.4 ± 3.3' 0 <t< td=""><td>~</td><td></td><td>intervention</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	~		intervention								
ele (44) 2002 Baseline data from prospective colord 54.0 ± 0.5 55.0 ± 0.6 0 <25 10 2003 Cross-sectional 33.4 ± 1.22 31.4 ± 7.5 0 0 <24 13) 2007 Cross-sectional 36.5 ± 7.2 31.4 ± 7.5 0 0 <24 13) 2007 Cross-sectional 36.5 ± 7.2 31.4 ± 7.5 0 0 <24 (31) 2008 Cross-sectional 36.5 ± 7.5 $34.4 \pm 1.3^{\circ}$ 27.3 20.5 <24 (31) 2008 Cross-sectional $20.5 \pm 1.6^{\circ}$ 27.5 0.5 <24 (31) 2008 Cross-sectional $55.4 \pm 3.3^{\circ}$ 0 0 0.5 <25 (31) 2008 Cross-sectional $44.8 \pm 16^{\circ}$ $55.4 \pm 3.3^{\circ}$ 0.5 $0.6 \pm 25.5^{\circ}$ (31) 2008 Cross-sectional $44.8 \pm 16^{\circ}$ $45.5 \pm 1.2^{\circ}$ $38.5 \pm 3.3^{\circ}$ 0.6° 0.6° 0.6° 0.6°			study (weight loss)								
$ \begin{array}{c cccccc} & & & & & & & & & & & & & & & & $	De Michele (44)	2002	Baseline data from	$54.0 \pm 0.9^*$	$55.0 \pm 0.8^{*}$	0	0	<25	>30	$23.0 \pm 0.1^{*}$	$33.8 \pm 0.3^{*}$
			prospective cohort								
	Yu (17)	2003	Cross-sectional	33.4 ± 12.3	34.1 ± 12.2	100	100	<24	>28	21.9 ± 1.9	32.8 ± 4.1
	Oflaz (7)	2003	Cross-sectional	30.6 ± 7.2	31.4 ± 7.5	0	0	<24	>30	20.4 ± 1.6	34.2 ± 3.8
	Marini (13)	2007	Cross-sectional	34 ± 9	35 ± 8	0	0	<27	>30	23.8 ± 2.8	37.7 ± 9.9
	Skilton (31)	2008	Cross-sectional	$42.8 \pm 2.5^*$	$44.4 \pm 1.3^*$	27.3	20.5	<24	>30	$21.9 \pm 0.4^*$	$44.6 \pm 1.6^*$
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Mizia-Stec (29)	2008	Cross-sectional	Control A	29.7 ± 6.2	0	0	Control A:	>30	Control A:	33.60 ± 2.90
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $				<35: 28.0 ± 7.6				20.8–27.6,		24.0 ± 3.8,	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $				Control B				Control B:		Control B:	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$				51.9				21.9–28.3		25.8 ± 2.9	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Yu (17)	2008	Cross-sectional	56.4 ±	3.3 [†]	0	0	<25	≥25	23.6 :	23.6 ± 3.7 [†]
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Stefan (45)	2008	Cross-sectional	$44.8 \pm 1.6^*$	$46.5 \pm 1.9^*$	16.7	38.6	<25	>30	22.0	34.0
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Fahs (33)	2009	Cross-sectional	25.7 ± 1.2*	$33.8 \pm 1.3^*$	100	100	<25.9	≥29.5	$23.6 \pm 0.3^{*}$	$32.8 \pm 0.5^*$
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Biasucci (4)	2010	Cross-sectional	48.4 ± 5.6	51.0 ± 6.2	38.5	57.1	NIL	NIL	23.2 ± 1.6	32.6 ± 2.5
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Blaha (46)	2011	Baseline data from	hsCRP < 2 :	hsCRP < 2 :	hsCRP $< 2: 61$	hsCRP $< 2:48$	<30	≥30	hsCRP < 2 :	hsCRP < 2 :
Prospective cohorthsCRP \geq 2:hsCRP \geq 2:hsCRP \geq 2:2011Cross-sectional31.0 ± 5.332.7 ± 5.352.652.62011Cross-sectional31.0 ± 5.332.7 ± 1.845.052.0<23			population-based	61.7 ± 11	62.5 ± 10	hsCRP \geq 2: 53	hsCRP≥ 2: 31			24.2 ± 3	30.6 ± 4
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$			prospective cohort	hsCRP \geq 2:	hsCRP \geq 2:					hsCRP \geq 2:	hsCRP \geq 2:
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$				63.0 ± 10	62.0 ± 10					24.8 ± 3	32.9 ± 5
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Ayer (36)	2011	Cross-sectional	31.0 ± 5.3	32.7 ± 5.3	52.6	52.6	18–25	>30	22.4 ± 1.6	44.1 ± 9.0
48) 2011 Cross-sectional, 39.7 ± 10.0 40.4 ± 11.8 33.9 NIL NIL Cross-sectional 39.7 ± 10.0 40.4 ± 11.8 33.9 NIL NIL case-control case-control 41.8 ± 11.2 44.7 ± 12.5 0 0 18.5-24.9 To 2013 Baseline data 45 ± 18 50 ± 13 48 20 <25 from prospective cohort from prospective cohort 1.5 from prospective cohort 1.5 from the cohort from the cohort 1.5 f	Park (47)	2011	Cross-sectional	52.0 ± 5.5	52.2 ± 6.1	45.0	52.0	<23	≥25	21.3 ± 1.1	26.3 ± 1.0
$ \begin{array}{c ccccc} case-control \\ 2012 & Cross-sectional \\ 2013 & Baseline data \\ 2013 & Baseline data \\ from prospective \\ cohort \\ cohort \\ \hline \\ $	Csongradi (48)	2011	Cross-sectional,	39.7 ± 10.0	40.4 ± 11.8	33.9	NIL	NIL	NIL	22.1 ± 2.0	37.7 ± 8.1
2012 Cross-sectional 41.8 ± 11.2 44.7 ± 12.5 0 0 18.5-24.9 2013 Baseline data 45 ± 18 50 ± 13 48 20 <25			case-control								
2013 Baseline data 45 ± 18 50 ± 13 48 20 <25	Ecemis (49)	2012	Cross-sectional	41.8 ± 11.2	44.7 ± 12.5	0	0	18.5–24.9	30.0–39.9	22.3 ± 1.9	34.9 ± 2.5
from prospective cohort Data presented as mean ± SD except: *Mean ≟ SE. †Value for controls and obesity combined. hsCRP, high-sensitivity C-reactive protein.	Aydin (12)	2013	Baseline data	45 ± 18	50 ± 13	48	20	<25	30–39.9	NIL	NIL
cohort Data presented as mean ± SD except: *Mean ± SE. †Value for controls and obesity combined. hsCRP, high-sensitivity C-reactive protein.			from prospective								
Data presented as mean ± SD except: *Mean ± SE. †Value for controls and obesity combined. hsCRP, high-sensitivity C-reactive protein.			cohort								
*Mean ± SE. ¹ Value for controls and obesity combined. hsCRP, high-sensitivity C-reactive protein.	Data presented as	mean ±	SD except:								
¹ Value for controls and obesity combined. hsCRP, high-sensitivity C-reactive protein.	*Mean ± SE.										
hsCRP, high-sensitivity C-reactive protein.	^T Value for controls	and obe	sity combined.								
	hsCRP, high-sens	itivity C-r	eactive protein.								

© 2017 The Authors

Obesity Science & Practice published by John Wiley & Sons Ltd, World Obesity and The Obesity Society. Obesity Science & Practice

	Ob	esity		Co	ntrols			Mean Difference	Mean Difference
Study or Subgroup	Mean [%]	SD [%]	Total	Mean [%]	SD [%]	Total	Weight	IV, Random, 95% CI [%] Yea	r IV, Random, 95% CI [%]
Hashimoto 1998	4.99	2.03	38	8.91	2.11	23	6.9%	-3.92 [-5.00, -2.84] 1998	8
Oflaz 2003	13.33	6.51	24	25.24	13.96	14	1.4%	-11.91 [-19.67, -4.15] 2003	3 +
Yu 2003	20.5	4.6	24	26.1	6.7	12	3.2%	-5.60 [-9.81, -1.39] 2003	3
Olson 2006	5.2	3.92	19	9.1	2.97	18	5.5%	-3.90 [-6.13, -1.67] 2006	6
Pulerwitz 2006	5.3	3.7	146	6.8	3.9	130	7.1%	-1.50 [-2.40, -0.60] 2006	6 -
Zhu 2007	6.54	3.27	78	11.25	3.98	172	7.1%	-4.71 [-5.65, -3.77] 2007	7 -
Skilton 2008	6.2	4.37	39	6.2	4.31	11	4.6%	0.00 [-2.89, 2.89] 2008	8
Mizia-Stec 2008	16.8	7.9	22	13.99	5.73	34	3.6%	2.81 [-1.01, 6.63] 2008	8
Fahs 2009	7.25	5.05	37	6.59	3.48	36	5.8%	0.66 [-1.32, 2.64] 2009	9
Patel 2009	10.8	6.24	48	14.6	7.07	50	4.9%	-3.80 [-6.44, -1.16] 2009	9
Lind 2009	7.9	6.4	19	8.9	5.4	19	3.6%	-1.00 [-4.77, 2.77] 2009	9
Biasucci 2010	7.53	5.47	35	7.33	3.68	13	4.9%	0.20 [-2.50, 2.90] 2010	0
Zhu 2010	7.3	3.5	14	10.7	3.3	11	4.9%	-3.40 [-6.08, -0.72] 2010	0
Ayer 2010	6.2	1.7	11	4.7	4.1	11	5.0%	1.50 [-1.12, 4.12] 2010	0 +
Ayer 2011	5.3	3.487	19	6.7	4.794	19	4.9%	-1.40 [-4.07, 1.27] 201	1
Mah 2011	5.78	1.75	8	7.31	0.85	8	6.6%	-1.53 [-2.88, -0.18] 201	1
Vinet 2011	3.3	2	16	5.7	1.6	16	6.7%	-2.40 [-3.65, -1.15] 201	1
Doupis 2011	6.1	4.7	37	8.4	3.5	40	6.0%	-2.30 [-4.16, -0.44] 201	1
Martin 2013	8.3	3.9	419	8.6	4.1	1043	7.4%	-0.30 [-0.75, 0.15] 2013	3 -
Total (95% CI)			1053			1680	100.0%	-1.92 [-2.92, -0.92]	•
Heterogeneity: Tau ² =	3.45; Chi ² =	131.40, c	f = 18	(P < 0.0000	1); l ² = 86	5%			
Test for overall effect:				,					-10 -5 0 5 10 Lower in Obesity Lower in Controls

Figure 1 Forest plot of mean difference in brachial FMD between adults with obesity and healthy weight adults.

	Ob	esity		Co	ntrols			Mean Difference	Mean Difference
Study or Subgroup	Mean [mm]	SD [mm]	Total	Mean [mm]	SD [mm]	Total	Weight	IV, Random, 95% CI [mm] Year	IV, Random, 95% CI [mm]
Karason 1999	0.81	0.16	31	0.76	0.18	35	2.9%	0.05 [-0.03, 0.13] 1999	
Ciccone 1999	0.952	0.254	132	0.85	0.212	107	4.3%	0.10 [0.04, 0.16] 1999	
Mavri 2001	0.72	0.17	43	0.59	0.12	19	3.3%	0.13 [0.06, 0.20] 2001	
De Michele 2002	1.02	0.18	83	0.94	0.1	92	5.7%	0.08 [0.04, 0.12] 2002	
Oflaz 2003	0.569	0.097	24	0.455	0.067	14	4.9%	0.11 [0.06, 0.17] 2003	
Yu 2003	0.5	0.02	24	0.34	0.19	12	1.9%	0.16 [0.05, 0.27] 2003	
Marini 2007	0.79	0.08	20	0.68	0.11	73	5.7%	0.11 [0.07, 0.15] 2007	
Mizia-Stec 2008	0.58	0.09	22	0.604	0.0614	34	5.7%	-0.02 [-0.07, 0.02] 2008	
Skilton 2008	0.75	0.12	39	0.65	0.1	11	3.6%	0.10 [0.03, 0.17] 2008	
Stefan 2008	0.54	0.23	127	0.51	0.15	54	4.5%	0.03 [-0.03, 0.09] 2008	
Yu 2008	0.79	0.12	163	0.75	0.11	355	7.9%	0.04 [0.02, 0.06] 2008	
Fahs 2009	0.52	0.061	37	0.44	0.06	36	7.3%	0.08 [0.05, 0.11] 2009	
Biasucci 2010	0.66	0.21	35	0.54	0.12	13	2.3%	0.12 [0.02, 0.22] 2010	
Ayer 2011	0.6	0.0871	19	0.51	0.0435	19	5.7%	0.09 [0.05, 0.13] 2011	
Blaha 2011	0.889	0.19	3496	0.849	0.193	3264	8.8%	0.04 [0.03, 0.05] 2011	-
Csongradi 2011	0.54	0.11	56	0.5	0.08	62	6.5%	0.04 [0.00, 0.08] 2011	
Park 2011	0.72	0.06	71	0.7	0.06	286	8.4%	0.02 [0.00, 0.04] 2011	
Ecemis 2012	0.6	0.2	25	0.4	0.1	25	2.7%	0.20 [0.11, 0.29] 2012	
Aydin 2013	0.61	0.15	375	0.55	0.18	488	7.9%	0.06 [0.04, 0.08] 2013	-
Total (95% CI)			4822			4999	100.0%	0.07 [0.05, 0.08]	•
Heterogeneity: Tau ² =	0.00; Chi ² = 80).82, df = 1	8 (P < 0	0.00001 ; $l^2 = 7$	78%			100 V 80 2000 1	
Test for overall effect:									-0.2 -0.1 0 0.1 0.2 Higher in Controls Higher in Obesity

Figure 2 Forest plot of mean difference in carotid IMT between adults with obesity and healthy weight adults.

stratified analyses, with the exception of studies of brachial FMD in participants aged >50 years, in which findings were relatively consistent.

Regarding methodological differences, analysis stratified by carotid IMT measurement methodology found no differences between subgroups (Figure 10). For the brachial FMD methodology, subgroups were analysed based on site of occlusion, which has important implications for the proportion of the response due to endothelial nitric oxide. The subgroup analysis showed some evidence that the association of obesity with lower FMD was more marked in studies which used distal (forearm) occlusion, than in studies which used proximal (upper arm) occlusion ($P_{heterogeneity} = 0.10$; Figure 6).

Assessment of publication bias

Funnel plots for both brachial FMD and carotid IMT demonstrate a lack of smaller studies (Figures 11 and 12). The funnel plot for brachial FMD shows a symmetrical distribution of studies about the mean effect size. The funnel plot for carotid IMT is slightly skewed to the right, indicating that smaller studies with negative results or reverse associations might not have been published.

Study or Subgroup Mean [%] SD [%] Total Mean [%] SD [%] Total Weight IV, Random, 95% CI [%] < 60 years old - <		Ob	esity		Co	ntrols			Mean Difference		Mean Difference
Hashimoto 1998 4.99 2.03 38 8.91 2.11 23 6.9% $-3.92 [-5.00, -2.84]$ 1998 Yu 2003 20.5 4.6 24 26.1 6.7 12 3.2% $-5.00 [-9.81, -1.39]$ 2003 Oflaz 2003 13.3 6.51 24 22.52 13.96 14 1.4% $-11.91 [-19.67, -4.15]$ 2006 Diazo206 5.2 3.92 19 9.1 2.97 18 5.5% $-3.90 [-6.13, -16.7]$ 2006 Zhu 2007 6.54 3.27 78 11.25 3.88 172 7.1% $-4.71 [-5.65, -3.77]$ 2007 Mizia-Stec 2008 16.8 7.9 22 13.99 5.73 34 3.6% 2.81 [-1.01, 6.63] 2008 Skitton 2006 6.2 4.37 39 6.2 4.31 11 4.6% 0.00 [-2.89, 2.89] 2008 Lind 2009 7.25 5.05 37 6.59 3.48 36 5.8% 0.66 [-1.32, 2.64] 2009 Zhu 2010 7.3 3.5 14 10.7 3.3 11 4.9% $-3.40 [-6.68, 0.72]$ 2010 Yine 2010 6.2 1.7 11 4.7 4.1 11 5.0% 1.50 [-1.12, 4.12] 2010 Yine 2011 6.2 1.7 11 4.7 4.1 11 5.0% 1.50 [-1.12, 4.12] 2010 Yine 2011 6.78 1.75 8 7.31 0.85 8 6.6% $-1.53 [-2.88, 0.18]$ 2011 Wah 2011 5.78 1.75 8 7.31 0.85 8 6.6% $-1.53 [-2.88, 0.18]$ 2011 Wartin 2013 8.3 3.9 419 8.6 4.1 1043 7.4% $-0.30 [-0.75, 0.15]$ 2011 Martin 2013 8.3 3.9 419 8.6 4.1 1043 7.4% $-0.30 [-0.75, 0.15]$ 2011 Martin 2013 8.3 3.9 419 8.6 4.1 1043 7.4% $-0.30 [-0.75, 0.15]$ 2011 Martin 2013 8.3 3.9 419 8.6 4.1 4.47 77.2% $-1.95 [-3.22, -0.69]$ Heterogeneity: Tau ² = 4.56; Chi ² = 126.28, df = 14 (P < 0.00001); P = 89% Test for overall effect: Z = 3.00 (P = 0.018) Test for overall effect: Z = 3.00 (P = 0.018); P = 39% Test for overall effect: Z = 3.00 (P = 0.018); P = 39% Test for overall effect: Z = 3.00 (P = 0.018); P = 39% Test for overall effect: Z = 3.00 (P = 0.018); P = 39% Test for overall effect: Z = 3.00 (P = 0.018); P = 39% Test for overall effect: Z = 3.00 (P = 0.018); P = 39% Test for overall effect: Z = 3.07 (P = 0.00001); P = 86% Test for overall effect: Z = 3.07 (P = 0.00001); P = 86% Test for overall effect: Z = 3.77 (P = 0.00001); P = 86% Test for overall effect: Z = 3.77 (P = 0.00001); P = 86% Test for overall effect: Z = 3.77 (P = 0.00001); P = 86% Test for overall effect: Z = 3.77 (P = 0.00001); P = 86% Test for overall effect: Z = 3.77 (P = 0.00001); P = 86% Test for overall ef	Study or Subgroup	Mean [%]	SD [%]	Total	Mean [%]	SD [%]	Total	Weight	IV, Random, 95% CI [%] Year	IV, Random, 95% CI [%]
Yu 2003 20.5 4.6 24 26.1 6.7 12 3.2% $-5.60[-9.81, -1.39]$ 2003 Oflaz 2003 13.33 6.51 24 25.24 13.96 14 1.4% $-119[-19.67, 4.15]$ 2003 Zhu 2007 6.54 3.27 78 11.25 3.88 172 7.1% $-4.71[-5.65, -3.77]$ 2007 Mizia-Stec 2008 16.8 7.9 22 13.99 5.73 34 3.6% $-2.81[-1.01, 6.63]$ 2008 Skitton 2008 6.2 4.37 39 6.2 4.31 11 4.6% 0.00[-2.89, 2.89] 2008 Lind 2009 7.9 6.4 19 8.9 5.4 19 3.6% $-1.00[-4.77, 2.77]$ 2009 Zhu 2010 7.3 3.5 14 10.7 3.3 11 4.9% $-3.40[-6.08, -0.72]$ 2010 Ayer 2010 6.2 1.7 11 4.7 4.1 11 5.0% $1.50[-1.12, 4.12]$ 2010 Vinet 2011 5.3 3.487 19 6.7 4.794 19 4.9% $-1.50[-2.40, -0.60]$ 2016 Ayer 2011 5.3 3.487 19 6.7 4.794 19 4.9% $-1.50[-2.40, -0.60]$ 2011 Marin 2013 5.3 3.47 19 6.7 4.794 19 4.9% $-1.50[-2.40, -0.60]$ 2014 Heterogeneity: Tau ² = 4.56; Chi ² = 126.28, df = 14 (P < 0.00001); P = 88% Test for overall effect: Z = 3.00 (P = 0.08); P = 39% Test for overall effect: Z = 3.00 (P = 0.002) > 50 years old Pulerwiz 2006 5.3 3.7 146 6.8 3.9 130 7.1% $-1.50[-2.40, -0.60]$ 2006 Patel 2009 10.8 6.24 48 14.6 7.07 50 4.9% $-3.80[-6.44, -1.16]$ 2009 > 1.92 [-2.50, 2.90] 2010 Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% $-2.30[-4.16, -0.44]$ 2011 	< 50 years old										
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Hashimoto 1998	4.99	2.03	38	8.91	2.11	23	6.9%	-3.92 [-5.00, -2.84]	1998	-
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Yu 2003	20.5	4.6	24	26.1	6.7	12	3.2%	-5.60 [-9.81, -1.39]	2003	
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Oflaz 2003	13.33	6.51	24	25.24	13.96	14	1.4%	-11.91 [-19.67, -4.15]	2003	←
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Olson 2006	5.2	3.92	19	9.1	2.97	18	5.5%	-3.90 [-6.13, -1.67]	2006	
Skilton 2008 6.2 4.37 39 6.2 4.31 11 4.6% 0.00 [$2.89, 2.89$] 2008 Lind 2009 7.9 6.4 19 8.9 5.4 19 3.6% -1.00 [$4.77, 2.77$] 2009 Zhu 2010 7.3 3.5 14 10.7 3.3 11 4.9% -3.40 [$-6.08, -0.72$] 2010 Ayer 2010 6.2 1.7 11 4.7 4.1 11 5.0% 1.50 [$-1.12, 4.12$] 2010 Vinet 2011 3.3 2 16 5.7 1.6 16 6.7% -2.40 [$-3.65, -1.15$] 2011 Mah 2011 5.78 1.75 8 7.31 0.85 8 6.6% -1.53 [$-2.88, -0.18$] 2011 Ayer 2011 5.3 3.487 19 6.7 4.794 19 4.9% -1.40 [$-4.07, 1.27$] 2011 Martin 2013 8.3 3.9 419 8.6 4.1 1043 7.4% -0.30 [$-0.75, 0.15$] 2013 Subtotal (95% CI) 787 1447 77.2% -1.95 [$-3.22, -0.69$] Heterogeneity: Tau ² = 4.56; Chi ² = 126.28, df = 14 ($P < 0.00001$); $P = 89\%$ Test for overall effect: Z = 3.03 ($P = 0.02$) Heterogeneity: Tau ² = 0.56; Chi ² = 4.92, df = 3 ($P = 0.18$); $P = 39\%$ Test for overall effect: Z = 3.00 ($P = 0.002$) Heterogeneity: Tau ² = 0.56; Chi ² = 4.92, df = 3 ($P = 0.18$); $P = 39\%$ Test for overall effect: Z = 3.00 ($P = 0.0002$) Total (95% CI) 1053 1680 100.0% -1.92 [$-2.92, -0.92$] Heterogeneity: Tau ² = 0.55; Chi ² = 4.92, df = 3 ($P = 0.18$); $P = 39\%$ Test for overall effect: Z = 3.07 ($P = 0.0002$)	Zhu 2007	6.54	3.27	78	11.25	3.98	172	7.1%	-4.71 [-5.65, -3.77]	2007	-
Lind 2009 7.9 6.4 19 8.9 5.4 19 3.6% -1.00 [-4.77, 2.77] 2009 Fahs 2009 7.25 5.05 37 6.59 3.48 36 5.5% 0.66 [-1.32, 2.64] 2009 Zhu 2010 7.3 3.5 14 10.7 3.3 11 4.9% -3.40 [-6.08, 0.72] 2010 Vinet 2011 3.3 2 16 5.7 1.6 16 6.7% -2.40 [-3.65, -1.15] 2011 Mah 2011 5.78 1.75 8 7.31 0.85 8 6.6% -1.53 [-2.88, -0.18] 2011 Martin 2013 8.3 3.9 419 8.6 4.1 1043 7.4% -0.30 [-0.75, 0.15] 2013 Subtotal (95% Cl) 787 1447 77.2% -1.95 [-3.22, -0.69] Heterogeneity: Tau ² = 4.56; Chi ² = 126.28, df = 14 ($P < 0.00001$); $P = 89\%$ Test for overall effect: Z = 3.00 ($P = 0.002$) > 50 years old Pulerwitz 2006 5.3 3.7 146 6.8 3.9 130 7.1% -1.50 [-2.40, -0.60] 2006 Patel 2009 10.8 6.24 48 14.6 7.07 50 4.9% -3.80 [-6.44, -1.16] 2009 Biasucci 2010 7.53 5.47 35 7.33 3.68 13 4.9% 0.22 [-2.50, 2.00] 2010 Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% -2.30 [-4.4, -1.16] 2009 Biasucci 2010 7.53 5.47 35 7.33 3.68 13 4.9% 0.22 [-2.50, 2.00] 2010 Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% -2.30 [-4.4, -1.16] 2011 Subtotal (95% Cl) 266 233 22.8% -1.79 [-2.96, -0.62] Heterogeneity: Tau ² = 0.56; Chi ² = 4.92, df = 3 ($P = 0.18$); $P = 39\%$ Test for overall effect: Z = 3.00 ($P = 0.003$) Total (95% Cl) 1053 1680 100.0% -1.92 [-2.92, -0.92] Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 ($P < 0.00001$); $P = 86\%$ Test for overall effect: Z = 3.77 ($P = 0.0002$)	Mizia-Stec 2008	16.8	7.9	22	13.99	5.73	34	3.6%	2.81 [-1.01, 6.63]	2008	
Fahs 2009 7.25 5.05 37 6.59 3.48 36 5.8% 0.66 [-1.32, 2.64] 2009 Zhu 2010 7.3 3.5 14 10.7 3.3 11 4.9% -3.40 [-6.08, -0.72] 2010 Ayer 2010 6.2 1.7 11 4.7 4.1 11 5.0% 1.50 [-1.12, 4.12] 2010 Vinet 2011 3.3 2 16 5.7 1.6 16 6.7% -2.40 [-3.65, -1.15] 2011 Mah 2011 5.78 1.75 8 7.31 0.85 8 6.6% -1.53 [-2.88, -0.18] 2011 Ayer 2011 5.3 3.487 19 6.7 4.794 19 4.9% -1.40 [-4.07, 1.27] 2011 Martin 2013 8.3 3.9 419 8.6 4.1 1043 7.4% -0.30 [-0.75, 0.15] 2013 Subtotal (95% CI) 787 1447 77.2% -1.95 [-3.22, -0.69] Heterogeneity: Tau ² = 4.56; Chi ² = 126.28, df = 14 (P < 0.00001); P = 89% Test for overall effect: Z = 3.00 (P = 0.002) > 50 years old Pulerwitz 2006 5.3 3.7 146 6.8 3.9 130 7.1% -1.50 [-2.40, -0.60] 2006 Patel 2009 10.8 6.24 48 14.6 7.07 50 4.9% -0.20 [-2.50, 2.90] 2010 Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% -2.30 [-4.16, -0.44] 2011 Subtotal (95% CI) 266 233 22.8% -1.79 [-2.96, -0.62] Heterogeneity: Tau ² = 0.56; Chi ² = 13.(P = 0.18); P = 39% Test for overall effect: Z = 3.00 (P = 0.003) Total (95% CI) 1053 1680 100.0% -1.92 [-2.92, -0.92] Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); P = 86% Test for overall effect: Z = 3.77 (P = 0.0002)	Skilton 2008	6.2	4.37	39	6.2	4.31	11	4.6%	0.00 [-2.89, 2.89]	2008	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Lind 2009	7.9	6.4	19	8.9	5.4	19	3.6%	-1.00 [-4.77, 2.77]	2009	
Aver 2010 6.2 1.7 11 4.7 4.1 11 5.0% 1.50 [-1.12, 4.12] 2010 Vinet 2011 3.3 2 16 5.7 1.6 16 6.7% -2.40 [-3.65, -1.15] 2011 Mah 2011 5.78 1.75 8 7.31 0.85 8 6.6% -1.53 [-2.88, -0.18] 2011 Martin 2013 8.3 3.9 419 8.6 4.1 1043 7.4% -0.30 [-0.75, 0.15] 2013 Subtotal (95% Cl) 787 1447 77.2% -1.95 [-3.22, -0.69] Heterogeneity: Tau ² = 4.56; Chi ² = 126.28, df = 14 (P < 0.00001); l ² = 89% Test for overall effect: Z = 3.03 (P = 0.002) > 50 years old Pulerwitz 2006 5.3 3.7 146 6.8 3.9 130 7.1% -1.50 [-2.40, -0.60] 2006 Patel 2009 10.8 6.24 48 14.6 7.07 50 4.9% -3.80 [-6.44, -1.16] 2009 Biasucci 2010 7.53 5.47 35 7.33 3.68 13 4.9% 0.20 [-2.50, 2.90] 2010 Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% -2.30 [-4.16, -0.44] 2011 Subtotal (95% Cl) 266 233 22.8% -1.79 [-2.96, -0.62] Heterogeneity: Tau ² = 0.56; Chi ² = 4.92, df = 3 (P = 0.18); l ² = 39% Test for overall effect: Z = 3.00 (P = 0.003) Total (95% Cl) 1053 1680 100.0% -1.92 [-2.92, -0.92] Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); l ² = 86% Test for overall effect: Z = 3.77 (P = 0.0002)	Fahs 2009	7.25	5.05	37	6.59	3.48	36	5.8%	0.66 [-1.32, 2.64]	2009	- -
Vinet 2011 3.3 2 16 5.7 1.6 16 6.7% -2.40 [-3.65, -1.15] 2011 Mah 2011 5.78 1.75 8 7.31 0.85 8 6.6% -1.53 [-2.88, -0.18] 2011 Ayer 2011 5.3 3.487 19 6.7 4.794 19 4.9% -1.40 [-4.07, 1.27] 2011 Martin 2013 8.3 3.9 419 8.6 4.1 1043 7.4% -0.30 [-0.75, 0.15] 2013 Subtotal (95% CI) 787 1447 77.2% -1.95 [-3.22, -0.69] Heterogeneity: Tau ² = 4.56; Chi ² = 126.28, df = 14 (P < 0.00001); l ² = 89% Test for overall effect: Z = 3.03 (P = 0.002) > 50 years old Pulerwitz 2006 5.3 3.7 146 6.8 3.9 130 7.1% -1.50 [-2.40, -0.60] 2006 Patel 2009 10.8 6.24 48 14.6 7.07 50 4.9% -3.80 [-6.44, -1.16] 2009 Biasucci 2010 7.53 5.47 35 7.33 3.68 13 4.9% 0.20 [-2.50, 2.90] 2010 Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% -2.30 [-4.16, -0.44] 2011 Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% -2.30 [-4.16, -0.44] 2011 Subtotal (95% CI) 266 233 22.8% -1.79 [-2.96, -0.62] Heterogeneity: Tau ² = 0.56; Chi ² = 4.92, df = 3 (P = 0.18); l ² = 39% Test for overall effect: Z = 3.00 (P = 0.003) Total (95% CI) 1053 1680 100.0% -1.92 [-2.92, -0.92] Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); l ² = 86% Test for overall effect: Z = 3.77 (P = 0.0002)	Zhu 2010	7.3	3.5	14	10.7	3.3	11	4.9%	-3.40 [-6.08, -0.72]	2010	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Ayer 2010	6.2	1.7	11	4.7	4.1	11	5.0%	1.50 [-1.12, 4.12]	2010	
Ayer 2011 5.3 3.487 19 6.7 4.794 19 4.9% -1.40 [4.07, 1.27] 2011 Martin 2013 8.3 3.9 419 8.6 4.1 1043 7.4% -0.30 [-0.75, 0.15] 2013 Subtotal (95% Cl) 787 1447 77.2% -1.95 [-3.22, -0.69] Heterogeneity: Tau ² = 4.56; Chi ² = 126.28, df = 14 (P < 0.00001); I ² = 89% Test for overall effect: Z = 3.03 (P = 0.002) > 50 years old Pulerwitz 2006 5.3 3.7 146 6.8 3.9 130 7.1% -1.50 [-2.40, -0.60] 2006 Patel 2009 10.8 6.24 48 14.6 7.07 50 4.9% -3.80 [-6.44, -1.16] 2009 Biasucci 2010 7.53 5.47 35 7.33 3.68 13 4.9% 0.20 [-2.50, 2.90] 2010 Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% -2.30 [-4.16, -0.44] 2011 Subtotal (95% Cl) 266 233 22.8% -1.79 [-2.96, -0.62] Heterogeneity: Tau ² = 0.56; Chi ² = 4.92, df = 3 (P = 0.18); I ² = 39% Test for overall effect: Z = 3.00 (P = 0.003) Total (95% Cl) 1053 1680 100.0% -1.92 [-2.92, -0.92] Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); I ² = 86% Test for overall effect: Z = 3.77 (P = 0.002)	Vinet 2011	3.3	2	16	5.7	1.6	16	6.7%	-2.40 [-3.65, -1.15]	2011	
Martin 2013 8.3 3.9 419 8.6 4.1 1043 7.4% -0.30 [-0.75, 0.15] 2013 Subtotal (95% Cl) 787 1447 77.2% -1.95 [-3.22, -0.69] -1.95 [-3.22, -0.69] Heterogeneity: Tau ² = 4.56; Chi ² = 126.28, df = 14 (P < 0.00001); I ² = 89% -1.95 [-3.22, -0.69] -1.95 [-3.22, -0.69] > 50 years old	Mah 2011	5.78	1.75	8	7.31	0.85	8	6.6%	-1.53 [-2.88, -0.18]	2011	
Subtotal (95% Cl) 787 1447 77.2% -1.95 [-3.22, -0.69] Heterogeneity: Tau ² = 4.56; Chi ² = 126.28, df = 14 (P < 0.00001); I ² = 89% Test for overall effect: Z = 3.03 (P = 0.002) > 50 years old Pulerwitz 2006 5.3 3.7 146 6.8 3.9 130 7.1% -1.50 [-2.40, -0.60] 2006 Patel 2009 10.8 6.24 48 14.6 7.07 50 4.9% -3.80 [-6.44, -1.16] 2009 Biasucci 2010 7.53 5.47 35 7.33 3.68 13 4.9% 0.20 [-2.50, 2.90] 2010 Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% -2.30 [-4.16, -0.44] 2011 Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% -2.30 [-4.16, -0.44] 2011 Subtotal (95% Cl) 266 233 22.8% -1.79 [-2.96, -0.62] Heterogeneity: Tau ² = 0.56; Chi ² = 4.92, df = 3 (P = 0.18); I ² = 39% Test for overall effect: Z = 3.00 (P = 0.0002) Total (95% Cl) 1053 1680 100.0% -1.92 [-2.92, -0.92] Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); I ² = 86% Test for overall effect: Z = 3.77 (P = 0.0002)	Ayer 2011	5.3	3.487	19	6.7	4.794	19	4.9%	-1.40 [-4.07, 1.27]	2011	
Heterogeneity: Tau ² = 4.56; Chi ² = 126.28, df = 14 (P < 0.00001); l ² = 89% Test for overall effect: Z = 3.03 (P = 0.002) > 50 years old Pulerwitz 2006 5.3 3.7 146 6.8 3.9 130 7.1% -1.50 [-2.40, -0.60] 2006 Patel 2009 10.8 6.24 48 14.6 7.07 50 4.9% -3.80 [-6.44, -1.16] 2009 Biasucci 2010 7.53 5.47 35 7.33 3.68 13 4.9% 0.20 [-2.50, 2.90] 2010 Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% -2.30 [-4.16, -0.44] 2011 Subtotal (95% CI) 266 233 22.8% -1.79 [-2.96, -0.62] Heterogeneity: Tau ² = 0.56; Chi ² = 4.92, df = 3 (P = 0.18); l ² = 39% Test for overall effect: Z = 3.00 (P = 0.0002) Total (95% CI) 1053 1680 100.0% -1.92 [-2.92, -0.92] Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); l ² = 86% Test for overall effect: Z = 3.77 (P = 0.0002)	Martin 2013	8.3	3.9		8.6	4.1				2013	. *
Test for overall effect: $Z = 3.03 (P = 0.002)$ > 50 years old Pulerwitz 2006 5.3 3.7 146 6.8 3.9 130 7.1% -1.50 [-2.40, -0.60] 2006 Patel 2009 10.8 6.24 48 14.6 7.07 50 4.9% -3.80 [-6.44, -1.16] 2009 Biasucci 2010 7.53 5.47 35 7.33 3.68 13 4.9% 0.20 [-2.50, 2.90] 2010 Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% -2.30 [-4.16, -0.44] 2011 Subtotal (95% CI) 266 233 22.8% -1.79 [-2.96, -0.62] Heterogeneity: Tau ² = 0.56; Chi ² = 4.92, df = 3 (P = 0.18); l ² = 39% Test for overall effect: Z = 3.00 (P = 0.0002) Total (95% CI) 1053 1680 100.0% -1.92 [-2.92, -0.92] Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); l ² = 86% Test for overall effect: Z = 3.77 (P = 0.0002)	Subtotal (95% CI)			787			1447	77.2%	-1.95 [-3.22, -0.69]		•
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Heterogeneity: Tau ² =	4.56; Chi ² =	126.28, 0	df = 14	(P < 0.0000	1); l ² = 89	9%				
Pulervitz 2006 5.3 3.7 146 6.8 3.9 130 7.1% -1.50 [-2.40, -0.60] 2006 Patel 2009 10.8 6.24 48 14.6 7.07 50 4.9% -3.80 [-6.44, -1.16] 2009 Biasucci 2010 7.53 5.47 35 7.33 3.68 13 4.9% 0.20 [-2.50, 2.90] 2010 Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% -2.30 [-4.16, -0.44] 2011 Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% -2.30 [-4.16, -0.44] 2011 Biasucci 2010 266 233 22.8% -1.79 [-2.96, -0.62] -0.62] Heterogeneity: Tau ² = 0.56; Chi ² = 4.92, df = 3 (P = 0.18); l ² = 39% Test for overall effect: Z = 3.00 (P = 0.0003) -1.92 [-2.92, -0.92] -1.92 -0 -5 0 5 10 Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); l ² = 86% -1.92 -2.92, -0.92] -10 -5 0 5 10 0 wer in On	Test for overall effect:	Z = 3.03 (P =	= 0.002)								
Patel 2009 10.8 6.24 48 14.6 7.07 50 4.9% -3.80 [- 6.44 , -1.16] 2009 Biasucci 2010 7.53 5.47 35 7.33 3.68 13 4.9% -3.80 [- 6.44 , -1.16] 2009 Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% -2.30 [- 4.16 , -0.44] 2011 Subtotal (95% CI) 266 233 22.8% -1.79 [- 2.96 , -0.62] -1.79 [- 2.96 , -0.62] Heterogeneity: Tau ² = 0.56; Chi ² = 4.92, df = 3 (P = 0.18); l ² = 39% Test for overall effect: Z = 3.00 (P = 0.003) -1.92 [- 2.92 , -0.92] -10 -5 0 5 10 Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); l ² = 86% -1.92 [- 2.92 , -0.92] -10 -5 0 5 10 Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); l ² = 86% -0 -0 -5 0 5 10 0 0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0	> 50 years old										
Biasucci 2010 7.53 5.47 35 7.33 3.68 13 4.9% 0.20 [-2.50, 2.90] 2010 Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% -2.30 [-4.16, -0.44] 2011 Subtotal (95% CI) 266 233 22.8% -1.79 [-2.96, -0.62] -1.79 [-2.96, -0.62] Heterogeneity: Tau ² = 0.56; Chi ² = 4.92, df = 3 (P = 0.18); l ² = 39% 7.53 1680 100.0% -1.92 [-2.92, -0.92] Total (95% CI) 1053 1680 100.0% -1.92 [-2.92, -0.92] -10 -5 0 5 10 Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); l ² = 86% -1.92 [-2.92, -0.92] -10 -5 0 5 10 Lower in Obesity Lower in Controls -10 -5 0 5 10	Pulerwitz 2006	5.3	3.7	146	6.8	3.9	130	7.1%	-1.50 [-2.40, -0.60]	2006	-
Doupis 2011 6.1 4.7 37 8.4 3.5 40 6.0% -2.30 $[-4.16, -0.44]$ 2011 Subtotal (95% CI) 266 233 22.8% -1.79 $[-2.96, -0.62]$ Heterogeneity: Tau ² = 0.56; Chi ² = 4.92, df = 3 (P = 0.18); l ² = 39% Test for overall effect: Z = 3.00 (P = 0.003) -1.92 $[-2.92, -0.92]$ Total (95% CI) 1053 1680 100.0% -1.92 $[-2.92, -0.92]$ Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); l ² = 86% -10 -5 0 5 10 Test for overall effect: Z = 3.77 (P = 0.0002) -10 -5 0 5 10	Patel 2009	10.8	6.24	48	14.6	7.07	50	4.9%	-3.80 [-6.44, -1.16]	2009	
Subtotal (95% CI) 266 233 22.8% -1.79 [-2.96, -0.62] Heterogeneity: Tau ² = 0.56; Chi ² = 4.92, df = 3 (P = 0.18); l ² = 39% Test for overall effect: Z = 3.00 (P = 0.003) -1.92 [-2.92, -0.92] Total (95% CI) 1053 1680 100.0% -1.92 [-2.92, -0.92] Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); l ² = 86% -1.92 [-2.92, -0.92] -10 Test for overall effect: Z = 3.77 (P = 0.0002) -10 (Destity) -0 (Destity) -0 (Destity)	Biasucci 2010	7.53	5.47	35	7.33	3.68	13	4.9%	0.20 [-2.50, 2.90]	2010	
Heterogeneity: Tau ² = 0.56; Chi ² = 4.92, df = 3 (P = 0.18); l ² = 39% Test for overall effect: Z = 3.00 (P = 0.003) Total (95% Cl) 1053 1680 100.0% -1.92 [-2.92, -0.92] Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); l ² = 86% Test for overall effect: Z = 3.77 (P = 0.0002) -10 -5 0 5 10 Lower in Obesity. Lower in Controls	Doupis 2011	6.1	4.7	37	8.4	3.5	40	6.0%	-2.30 [-4.16, -0.44]	2011	
Test for overall effect: Z = 3.00 (P = 0.003) Total (95% CI) 1053 Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); l ² = 86% Test for overall effect: Z = 3.77 (P = 0.0002)	Subtotal (95% CI)			266			233	22.8%	-1.79 [-2.96, -0.62]		•
Total (95% CI) 1053 1680 100.0% -1.92 [-2.92, -0.92] Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); l ² = 86% -10 -5 0 5 10 Test for overall effect: Z = 3.77 (P = 0.0002) -10 -5 0 5 10	Heterogeneity: Tau ² =	0.56; Chi ² =	4.92, df =	= 3 (P =	= 0.18); l ² = 3	39%					
Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); I ² = 86% Test for overall effect: Z = 3.77 (P = 0.0002)	Test for overall effect:	Z = 3.00 (P =	= 0.003)								
Heterogeneity: Tau ² = 3.45; Chi ² = 131.40, df = 18 (P < 0.00001); I ² = 86% Test for overall effect: Z = 3.77 (P = 0.0002)	Total (95% CI)			1053			1680	100.0%	-1.92 [-2.92, -0.92]		◆
Test for overall effect: Z = 3.77 (P = 0.0002) -10 -5 0 5 10 Lower in Obesity Lower in Controls	Heterogeneity: Tau ² =	3.45; Chi ² =	131.40. c	df = 18	(P < 0.0000	1); l² = 86	5%				
					,						
					$P = 0.86$), $ ^2$	= 0%					Lower In Obesity Lower In Controls

Figure 3 Brachial FMD and obesity: analysis stratified by age. Forest plot of mean difference in brachial FMD between adults with obesity and healthy weight adults stratified by age above and below 50 years.

	Ob	esity		Co	ntrols			Mean Difference		Mean Difference
Study or Subgroup	Mean [%]	SD [%]	Total	Mean [%]	SD [%]	Total	Weight	IV, Random, 95% CI [%]	Year	IV, Random, 95% CI [%]
Males		54. 1995								
Hashimoto 1998	4.99	2.03	38	8.91	2.11	23	13.3%	-3.92 [-5.00, -2.84]	1998	- -
Yu 2003	20.5	4.6	24	26.1	6.7	12	6.5%	-5.60 [-9.81, -1.39]		
Zhu 2010	7.3	3.5	14	10.7	3.3	11	9.7%	-3.40 [-6.08, -0.72]	2010	
Vinet 2011	3.3	2	16	5.7	1.6	16	13.0%	-2.40 [-3.65, -1.15]	2011	
Mah 2011	5.78	1.75	8	7.31	0.85	8	12.8%	-1.53 [-2.88, -0.18]	2011	
Martin 2013	8.3	3.9	419	8.6	4.1	1043	14.2%	-0.30 [-0.75, 0.15]	2013	
Subtotal (95% CI)			519			1113	69.4%	-2.51 [-4.15, -0.88]		◆
Heterogeneity: Tau ² =	3.29; Chi ² =	50.27. df	= 5 (P	< 0.00001);	$ ^2 = 90\%$					
Test for overall effect:										
Females										
Oflaz 2003	13.33	6.51	24	25.24	13.96	14	2.8%	-11.91 [-19.67, -4.15]	2003 +	
Olson 2006	5.2	3.92	19	9.1	2.97	18	10.7%	-3.90 [-6.13, -1.67]	2006	
Mizia-Stec 2008	16.8	7.9	22	13.99	5.73	34	7.2%	2.81 [-1.01, 6.63]	2008	+
Patel 2009	10.8	6.24	48	14.6	7.07	50	9.8%	-3.80 [-6.44, -1.16]	2009	
Subtotal (95% CI)			113			116	30.6%	-3.30 [-7.14, 0.54]		
Heterogeneity: Tau ² =	11.22; Chi ² =	14.90, d	if = 3 (F	P = 0.002); P	² = 80%					
Test for overall effect:										
Total (95% CI)			632			1229	100.0%	-2.69 [-4.15, -1.23]		◆
Heterogeneity: Tau ² =	3.86; Chi ² =	71.34, df	= 9 (P	< 0.00001);	l² = 87%					
Test for overall effect:			•	,.						-10 -5 0 5 10
Test for subgroup diffe	•			- 0 74) 12	- 00/					Lower in Obesity Lower in Controls

Figure 4 Brachial FMD and obesity: analysis stratified by gender. Forest plot of mean difference in brachial FMD between adults with obesity and healthy weight adults stratified by gender.

Discussion

The results of this systematic review and meta-analysis indicate that obesity is associated with functional and

structural changes to the arterial vasculature, specifically lower brachial FMD and greater carotid IMT. This evidence of worsened arterial endothelial function and increased subclinical atherosclerosis is consistent with

© 2017 The Authors Obesity Science & Practice published by John Wiley & Sons Ltd, World Obesity and The Obesity Society. Obesity Science & Practice

	Ob	oesity		Co	ntrols			Mean Difference		Mean Difference
Study or Subgroup		SD [%]	Total	Mean [%]	SD [%]	Total	Weight	IV, Random, 95% CI [%]	Year	IV, Random, 95% CI [%]
Non WHO Definition	of Obesity									
Hashimoto 1998	4.99	2.03	38	8.91	2.11	23	6.9%	-3.92 [-5.00, -2.84]	1998	-
Oflaz 2003	13.33	6.51	24	25.24	13.96	14	1.4%	-11.91 [-19.67, -4.15]	2003	·
Yu 2003	20.5	4.6	24	26.1	6.7	12	3.2%	-5.60 [-9.81, -1.39]	2003	
Skilton 2008	6.2	4.37	39	6.2	4.31	11	4.6%	0.00 [-2.89, 2.89]	2008	
Mizia-Stec 2008	16.8	7.9	22	13.99	5.73	34	3.6%	2.81 [-1.01, 6.63]	2008	
Lind 2009	7.9	6.4	19	8.9	5.4	19	3.6%	-1.00 [-4.77, 2.77]	2009	
Fahs 2009	7.25	5.05	37	6.59	3.48	36	5.8%	0.66 [-1.32, 2.64]	2009	
Zhu 2010	7.3	3.5	14	10.7	3.3	11	4.9%	-3.40 [-6.08, -0.72]	2010	
Biasucci 2010	7.53	5.47	35	7.33	3.68	13	4.9%	0.20 [-2.50, 2.90]	2010	
Doupis 2011	6.1	4.7	37	8.4	3.5	40	6.0%	-2.30 [-4.16, -0.44]	2011	
Mah 2011	5.78	1.75	8	7.31	0.85	8	6.6%	-1.53 [-2.88, -0.18]	2011	
Martin 2013	8.3	3.9	419	8.6	4.1	1043	7.4%	-0.30 [-0.75, 0.15]	2013	
Subtotal (95% CI)			716			1264	58.9%	-1.57 [-2.85, -0.29]		•
Heterogeneity: Tau ² = Test for overall effect:			= 11 (F	<pre>> < 0.00001)</pre>); l ² = 830	%				
rest for overall effect.	2 - 2.40 (P -	- 0.02)								
WHO Definition of Ob	pesity									
Pulerwitz 2006	5.3	3.7	146	6.8	3.9	130	7.1%	-1.50 [-2.40, -0.60]	2006	-
Olson 2006	5.2	3.92	19	9.1	2.97	18	5.5%	-3.90 [-6.13, -1.67]	2006	
Zhu 2007	6.54	3.27	78	11.25	3.98	172	7.1%	-4.71 [-5.65, -3.77]	2007	-
Patel 2009	10.8	6.24	48	14.6	7.07	50	4.9%	-3.80 [-6.44, -1.16]	2009	
Ayer 2010	6.2	1.7	11	4.7	4.1	11	5.0%	1.50 [-1.12, 4.12]	2010	
Vinet 2011	3.3	2	16	5.7	1.6	16	6.7%	-2.40 [-3.65, -1.15]	2011	
Ayer 2011	5.3	3.487	19	6.7	4.794	19	4.9%	-1.40 [-4.07, 1.27]	2011	
Subtotal (95% CI)			337			416	41.1%	-2.43 [-3.90, -0.96]		•
Heterogeneity: Tau ² =	2.98; Chi ² =	37.17, df	= 6 (P	< 0.00001);	l ² = 84%					
Test for overall effect:	Z = 3.24 (P =	= 0.001)	•							
Total (95% CI)			1053			1680	100.0%	-1.92 [-2.92, -0.92]		•
Heterogeneity: Tau ² =	3.45: Chi ² =	131.40. 0	if = 18	(P < 0.0000	1): l ² = 86	5%				
Test for overall effect:					.,,					-10 -5 0 5 10
Test for subgroup diffe				$P = 0.39$ I^2	= 0%					Lower in Obesity Lower in Controls

Test for subgroup differences: $Chi^2 = 0.75$, df = 1 (P = 0.39), l² = 0%

Figure 5 Brachial FMD and obesity: analysis stratified by obesity and healthy weight criteria. Forest plot of mean difference in brachial FMD between adults with obesity and healthy weight adults stratified by use of World Health Organization criteria (Controls <25 kg m⁻², Obesity \geq 30 kg m⁻²), or alternative BMI cut-points.

theoretically meaningful differences in the risk of cardiovascular events. Specifically, the impairment of brachial FMD is consistent with a 12 to 33% higher risk of cardiovascular events (10), and the differences in carotid IMT are associated with a 7 to 12% higher risk of myocardial infarction and a 9 to 14% higher risk of stroke (11).

Cardiometabolic risk profile in individuals with obesity may contribute to the poor vascular health observed in this condition. Indeed, brachial FMD is impaired, and carotid IMT is increased in people with the metabolic syndrome (12-14). Approximately 64% of the risk of coronary artery disease events attributable to obesity are due to altered levels of the total cholesterol to HDL cholesterol ratio, systolic blood pressure and diabetes mellitus (15). Studies that included only adults with obesity and a specific comorbidity were specifically excluded, in order to at least partially limit the impact of these comorbidities. However, the rates of non-selected comorbidities remained high overall and may have contributed to the magnitude of the vascular health disturbances observed. There has been considerable discussion of metabolically healthy obesity, and as noted, the lack of consistent findings formed the basis for this current meta-analysis. Identification of a phenotype of people with obesity and optimal vascular health is beyond the scope of the current study, although if such a phenotype exists, it may relate to adipose tissue distribution (16,17), adipokine profile or genetic predisposition.

Subgroup analysis based on the site of occlusion for arterial endothelial function testing found some evidence for a greater difference between adults with obesity and those with healthy weight in studies utilizing the forearm occlusion method than in those with an upper arm occlusion. This may be due to the different underlying mechanisms of vasodilation in response to occlusion from these two sites, with the forearm occlusion eliciting vasodilatation through predominantly nitric oxide mediated pathways, and upper arm occlusion via both endothelium-derived nitric oxide and ischemic metabolites (18,19). Accordingly, these findings are consistent with obesity being associated with worsened endothelial function, and in particular, nitric oxide mediated vasodilation, putatively via enhanced oxidative stress, increased production of inflammatory cytokines and a direct effect of some adipokines and obesityrelated peptides (20).

Interestingly, the difference in FMD observed is less than that described in a recent meta-analysis of weight

	Ob	esity		Co	ntrols			Mean Difference		Mean Difference
Study or Subgroup	Mean [%]	SD [%]	Total	Mean [%]	SD [%]	Total	Weight	IV, Random, 95% CI [%] Year	IV, Random, 95% CI [%]
Forearm occlusion										
Hashimoto 1998	4.99	2.03	38	8.91	2.11	23	6.9%	-3.92 [-5.00, -2.84]	1998	-
Yu 2003	20.5	4.6	24	26.1	6.7	12	3.2%	-5.60 [-9.81, -1.39]	2003	
Oflaz 2003	13.33	6.51	24	25.24	13.96	14	1.4%	-11.91 [-19.67, -4.15]	2003	←
Olson 2006	5.2	3.92	19	9.1	2.97	18	5.5%	-3.90 [-6.13, -1.67]	2006	
Zhu 2007	6.54	3.27	78	11.25	3.98	172	7.1%	-4.71 [-5.65, -3.77]	2007	-
Skilton 2008	6.2	4.37	39	6.2	4.31	11	4.6%	0.00 [-2.89, 2.89]	2008	
Lind 2009	7.9	6.4	19	8.9	5.4	19	3.6%	-1.00 [-4.77, 2.77]	2009	
Ayer 2010	6.2	1.7	11	4.7	4.1	11	5.0%	1.50 [-1.12, 4.12]	2010	
Biasucci 2010	7.53	5.47	35	7.33	3.68	13	4.9%	0.20 [-2.50, 2.90]	2010	_
Ayer 2011	5.3	3.487	19	6.7	4.794	19	4.9%	-1.40 [-4.07, 1.27]	2011	
Vinet 2011	3.3	2	16	5.7	1.6	16	6.7%	-2.40 [-3.65, -1.15]	2011	
Doupis 2011	6.1	4.7	37	8.4	3.5	40	6.0%	-2.30 [-4.16, -0.44]	2011	
Mah 2011	5.78	1.75	8	7.31	0.85	8	6.6%	-1.53 [-2.88, -0.18]	2011	
Subtotal (95% CI)			367			376	66.3%	-2.38 [-3.53, -1.24]		•
Heterogeneity: Tau ² =	2.83; Chi ² =	52.00, df	= 12 (F	<pre>0.00001</pre>); l ² = 779	6				
Test for overall effect:	Z = 4.10 (P <	< 0.0001)								
Upper arm occlusion										
Pulerwitz 2006	5.3	3.7	146	6.8	3.9	130	7.1%	-1.50 [-2.40, -0.60]	2006	-
Mizia-Stec 2008	16.8	7.9	22	13.99	5.73	34	3.6%	2.81 [-1.01, 6.63]	2008	+
Patel 2009	10.8	6.24	48	14.6	7.07	50	4.9%	-3.80 [-6.44, -1.16]	2009	
Fahs 2009	7.25	5.05	37	6.59	3.48	36	5.8%	0.66 [-1.32, 2.64]	2009	- -
Zhu 2010	7.3	3.5	14	10.7	3.3	11	4.9%	-3.40 [-6.08, -0.72]	2010	
Martin 2013	8.3	3.9	419	8.6	4.1	1043	7.4%	-0.30 [-0.75, 0.15]	2013	.1
Subtotal (95% CI)			686			1304	33.7%	-1.01 [-2.21, 0.20]		•
Heterogeneity: Tau ² =	1.33; Chi ² =	20.02, df	= 5 (P	= 0.001); l ²	= 75%					
Test for overall effect:	Z = 1.63 (P =	= 0.10)								
Total (95% CI)			1053			1680	100.0%	-1.92 [-2.92, -0.92]		•
Heterogeneity: Tau ² =	3.45; Chi ² =	131.40, 0	df = 18	(P < 0.0000	1); l² = 86	5%				-10 -5 0 5 10
Test for overall effect:	Z = 3.77 (P =	= 0.0002)								Lower in Obesity Lower in Controls
	01.10				00 00/					Lower in Obesity Lower in Controls

Test for subgroup differences: Chi² = 2.64, df = 1 (P = 0.10), $I^2 = 62.2\%$

Figure 6 Brachial FMD and obesity: analysis stratified by site of occlusion. Forest plot of mean difference in brachial FMD between adults with obesity and healthy weight adults stratified by site of occlusion: forearm (distal to site of scan) and upper arm occlusion (proximal to site of scan).

Study or Subgroup	Mean [mm]	esity	Tetal		ntrols	Tetal	Malabl	Mean Difference IV, Random, 95% CI [mm]	Veen	Mean Difference IV, Random, 95% CI [mm]
< 50 years old	mean [mm]	SD [mm]	Total	wean [mm]	SD [mm]	Total	weight	IV, Random, 95% CI [mm]	rear	IV, Random, 95% CI [mm]
	0.050	0.054	100	0.05	0.040	407	1.00/	0.40 (0.04, 0.40)	1000	· · · · · · · · · · · · · · · · · · ·
Ciccone 1999	0.952	0.254	132	0.85	0.212	107	4.3%		1999	
Karason 1999	0.81	0.16	31	0.76	0.18	35	2.9%		1999	
Mavri 2001	0.72	0.17	43	0.59	0.12	19	3.3%		2001	
Yu 2003	0.5	0.02	24	0.34	0.19	12	1.9%	t t t	2003	
Oflaz 2003	0.569	0.097	24	0.455	0.067	14	4.9%		2003	
Marini 2007	0.79	0.08	20	0.68	0.11	73	5.7%		2007	
Mizia-Stec 2008	0.58	0.09	22	0.604	0.0614	34	5.7%	· · · · · · · · · · · · · · · · · · ·	2008	
Skilton 2008	0.75	0.12	39	0.65	0.1	11	3.6%	0.10 [0.03, 0.17]	2008	
Stefan 2008	0.54	0.23	127	0.51	0.15	54	4.5%	0.03 [-0.03, 0.09]	2008	+
Fahs 2009	0.52	0.061	37	0.44	0.06	36	7.3%	0.08 [0.05, 0.11]	2009	
Blaha 2011	0.889	0.19	3496	0.849	0.193	3264	8.8%	0.04 [0.03, 0.05]	2011	-
Ayer 2011	0.6	0.0871	19	0.51	0.0435	19	5.7%	0.09 [0.05, 0.13]	2011	· · · · ·
Csongradi 2011	0.54	0.11	56	0.5	0.08	62	6.5%	0.04 [0.00, 0.08]	2011	
Ecemis 2012	0.6	0.2	25	0.4	0.1	25	2.7%	0.20 [0.11, 0.29]	2012	s
Aydin 2013	0.61	0.15	375	0.55	0.18	488	7.9%	0.06 [0.04, 0.08]	2013	
Subtotal (95% CI)			4470			4253	75.7%	0.08 [0.05, 0.10]		•
Heterogeneity: Tau ² =	0.00; Chi ² = 62	2.94, df = 1	4 (P < 0	0.00001); I ² = 7	'8%					
Test for overall effect:	Z = 6.88 (P < 0	0.00001)								
> 50 years old		7.27072720	10000		1000					10 m 10 m
De Michele 2002	1.02	0.18	83	0.94	0.1	92	5.7%		2002	
Yu 2008	0.79	0.12	163	0.75	0.11	355	7.9%		2008	-
Biasucci 2010	0.66	0.21	35	0.54	0.12	13	2.3%		2010	
Park 2011	0.72	0.06	71	0.7	0.06	286	8.4%	0.02 [0.00, 0.04]	2011	
Subtotal (95% CI)			352			746	24.3%	0.05 [0.02, 0.08]		-
Heterogeneity: Tau ² =	0.00; Chi ² = 10).68, df = 3	(P = 0.	01); l ² = 72%						
Test for overall effect:	Z = 3.17 (P = 0	0.002)								
Total (95% CI)			4822			4999	100.0%	0.07 [0.05, 0.08]		•
Heterogeneity: Tau ² =	0.00. Chi ² = 80	82 df = 1		0.00001 · $l^2 = 7$	8%	100007070			_	
Test for overall effect:			0,000		070					-0.2 -0.1 0 0.1 0.2
										Higher in Controls Higher in Obesity

Figure 7 Carotid IMT and obesity: analysis stratified by age. Forest plot of mean difference in carotid IMT between adults with obesity and healthy weight people stratified by age above and below 50 years.

© 2017 The Authors

Obesity Science & Practice published by John Wiley & Sons Ltd, World Obesity and The Obesity Society. Obesity Science & Practice

	Ob	pesity		Co	ntrols			Mean Difference		Mean Difference
Study or Subgroup	Mean [mm]	SD [mm]	Total	Mean [mm]	SD [mm]	Total	Weight	IV, Random, 95% CI [mm]	Year	IV, Random, 95% CI [mm]
Females										
De Michele 2002	1.02	0.18	83	0.94	0.1	92	14.6%	0.08 [0.04, 0.12]	2002	
Oflaz 2003	0.569	0.097	24	0.455	0.067	14	13.4%	0.11 [0.06, 0.17]	2003	
Marini 2007	0.79	0.08	20	0.68	0.11	73	14.6%	0.11 [0.07, 0.15]	2007	
Mizia-Stec 2008	0.58	0.09	22	0.604	0.0614	34	14.7%	-0.02 [-0.07, 0.02]	2008	
Yu 2008	0.79	0.12	163	0.75	0.11	355	17.0%	0.04 [0.02, 0.06]	2008	
Ecemis 2012	0.6	0.2	25	0.4	0.1	25	9.2%	0.20 [0.11, 0.29]	2012	
Subtotal (95% CI)			337			593	83.5%	0.08 [0.03, 0.13]		
Heterogeneity: Tau ² =	0.00; Chi ² = 37	7.68, df = 5	(P < 0.	00001); l ² = 87	7%					
Test for overall effect:	Z = 3.26 (P = 0	0.001)								
Males										
Fahs 2009	0.52	0.061	37	0.44	0.06	36	16.5%	0.08 [0.05, 0.11]	2009	
Subtotal (95% CI)			37			36	16.5%	0.08 [0.05, 0.11]		•
Heterogeneity: Not app	olicable									17.
Test for overall effect:		0.00001)								
	·									
Total (95% CI)			374			629	100.0%	0.08 [0.04, 0.12]		
Heterogeneity: Tau ² =	0.00; Chi ² = 39	9.71, df = 6	(P < 0.	00001); l ² = 85	5%				-	-0.2 -0.1 0 0.1 0.2
Test for overall effect:	Z = 4.02 (P < 0	0.0001)								-0.2 -0.1 0 0.1 0.2 Higher in Controls Higher in Obesity
Test for subgroup diffe	rences: Chi ² =	0.00, df =	1 (P = 0	0.98), I ² = 0%						Higher In Controls Higher In Obesity

Figure 8 Carotid IMT and obesity: analysis stratified by gender. Forest plot of mean difference in carotid IMT between adults with obesity and healthy weight people stratified by gender.

	O	pesity		Co	ntrols			Mean Difference		Mean Difference
Study or Subgroup		SD [mm]	Total	Mean [mm]	SD [mm]	Total	Weight	IV, Random, 95% CI [mm]	Year	IV, Random, 95% CI [mm]
Non WHO Definition	of Obesity									
Ciccone 1999	0.952	0.254	132	0.85	0.212	107	4.3%	0.10 [0.04, 0.16]	1999	
Karason 1999	0.81	0.16	31	0.76	0.18	35	2.9%	0.05 [-0.03, 0.13]	1999	
Mavri 2001	0.72	0.17	43	0.59	0.12	19	3.3%	0.13 [0.06, 0.20]	2001	
Oflaz 2003	0.569	0.097	24	0.455	0.067	14	4.9%	0.11 [0.06, 0.17]	2003	
Yu 2003	0.5	0.02	24	0.34	0.19	12	1.9%	0.16 [0.05, 0.27]	2003	· · · · · · · · · · · · · · · · · · ·
Marini 2007	0.79	0.08	20	0.68	0.11	73	5.7%	0.11 [0.07, 0.15]	2007	
Skilton 2008	0.75	0.12	39	0.65	0.1	11	3.6%	0.10 [0.03, 0.17]	2008	
Mizia-Stec 2008	0.58	0.09	22	0.604	0.0614	34	5.7%	-0.02 [-0.07, 0.02]	2008	
Yu 2008	0.79	0.12	163	0.75	0.11	355	7.9%	0.04 [0.02, 0.06]	2008	
Fahs 2009	0.52	0.061	37	0.44	0.06	36	7.3%	0.08 [0.05, 0.11]	2009	
Biasucci 2010	0.66	0.21	35	0.54	0.12	13	2.3%	0.12 [0.02, 0.22]	2010	
Csongradi 2011	0.54	0.11	56	0.5	0.08	62	6.5%	0.04 [0.00, 0.08]	2011	
Blaha 2011	0.889	0.19	3496	0.849	0.193	3264	8.8%	0.04 [0.03, 0.05]	2011	+
Park 2011	0.72	0.06	71	0.7	0.06	286	8.4%	0.02 [0.00, 0.04]	2011	
Subtotal (95% CI)			4193			4321	73.7%	0.06 [0.04, 0.08]		•
Heterogeneity: Tau ² =	0.00; Chi ² = 6	0.11, df = 1	3 (P <)	0.00001); I ² =	78%					1.75 x 4
Test for overall effect:	Z = 6.37 (P < 6	0.00001)								
WHO Definition of O	besity									
De Michele 2002	1.02	0.18	83	0.94	0.1	92	5.7%	0.08 [0.04, 0.12]	2002	
Stefan 2008	0.54	0.23	127	0.51	0.15	54	4.5%			
Aver 2011	0.6	0.0871	19		0.0435	19	5.7%	0.09 [0.05, 0.13]		
Ecemis 2012	0.6	0.2	25	0.4	0.1	25	2.7%	0.20 [0.11, 0.29]		· · · · · · · · · · · · · · · · · · ·
Aydin 2013	0.61	0.15	375		0.18	488	7.9%	0.06 [0.04, 0.08]		
Subtotal (95% CI)			629			678	26.3%	0.08 [0.05, 0.12]		•
Heterogeneity: Tau ² =	0.00; Chi ² = 1;	2.16, df = 4	(P = 0)	.02); l ² = 67%						
Test for overall effect:			•							
Total (95% CI)			4822			4999	100.0%	0.07 [0.05, 0.08]		•
Heterogeneity: Tau ² =	0.00 Chi ² = 8	0.82 df = 1		$0.00001) \cdot l^2 = 1$	78%				_	
Test for overall effect:			0 (1 1)		0.0					-0.2 -0.1 0 0.1 0.2
Test for subgroup diffe			1 (P = 4	(141) $l^2 = 0%$						Higher in Controls Higher in Obesity
rescion subgroup unie	ences. Chi	0.05, 01 -	1 (12) = 1	0.41), 1' = 0.76						

Figure 9 Carotid IMT and obesity: analysis stratified by obesity and healthy weight criteria. Forest plot of mean difference in carotid IMT between adults with obesity and healthy weight adults stratified by use of World Health Organization criteria (Controls <25 kg m⁻², Obesity \geq 30 kg m⁻²), or alternative BMI cut-points.

loss and FMD (8), in which the net effect of weight loss on FMD was an improvement of 3.29% (absolute units). It is not clear why the beneficial effect of weight loss on endothelial function would be greater than the detrimental effect of obesity, although this may potentially relate to energy balance at the time of assessment or an independent effect of concurrent improvements in nutrition and physical activity. This systematic review and meta-analysis has a number of strengths. First, there has been no previous systematic review or meta-analysis on obesity and these two measures of vascular health (brachial FMD and carotid IMT), both of which are established methodologies that have well-documented associations with cardiovascular outcomes. A second reviewer independently screened all titles and abstracts identified

	OI	besity		Co	ntrols			Mean Difference		Mean Difference
Study or Subgroup	Mean [mm]	SD [mm]	Total	Mean [mm]	SD [mm]	Total	Weight	IV, Random, 95% CI [mm]	Year	IV, Random, 95% CI [mm]
Automated / Semi-au	utomated									
Karason 1999	0.81	0.16	31	0.76	0.18	35	4.3%	0.05 [-0.03, 0.13]	1999	
De Michele 2002	1.02	0.18	83	0.94	0.1	92	8.4%	0.08 [0.04, 0.12]	2002	
Skilton 2008	0.75	0.12	39	0.65	0.1	11	5.3%	0.10 [0.03, 0.17]	2008	
Ayer 2011	0.6	0.0871	19	0.51	0.0435	19	8.4%	0.09 [0.05, 0.13]	2011	
Park 2011	0.72	0.06	71	0.7	0.06	286	12.5%	0.02 [0.00, 0.04]	2011	
Subtotal (95% CI)			243			443	39.0%	0.06 [0.02, 0.11]		
Heterogeneity: Tau ² =	0.00; Chi ² = 1	7.09, df = 4	(P = 0.	.002); I ² = 77%						
Test for overall effect:	Z = 3.13 (P =	0.002)								
Not automated										
Mavri 2001	0.72	0.17	43	0.59	0.12	19	5.0%	0.13 [0.06, 0.20]	2001	
Yu 2008	0.79	0.12	163	0.75	0.11	355	11.7%	0.04 [0.02, 0.06]	2008	
Mizia-Stec 2008	0.58	0.09	22	0.604	0.0614	34	8.5%	-0.02 [-0.07, 0.02]	2008	
Fahs 2009	0.52	0.061	37	0.44	0.06	36	10.8%	0.08 [0.05, 0.11]	2009	
Biasucci 2010	0.66	0.21	35	0.54	0.12	13	3.5%	0.12 [0.02, 0.22]	2010	
Csongradi 2011	0.54	0.11	56	0.5	0.08	62	9.7%	0.04 [0.00, 0.08]	2011	
Aydin 2013	0.61	0.15	375	0.55	0.18	488	11.7%	0.06 [0.04, 0.08]	2013	
Subtotal (95% CI)			731			1007	61.0%	0.05 [0.03, 0.08]		•
Heterogeneity: Tau ² =	0.00; Chi ² = 24	4.30, df = 6	(P = 0.	0005); l ² = 75	%					
Test for overall effect:	Z = 3.93 (P <	0.0001)								
Total (95% CI)			974			1450	100.0%	0.06 [0.04, 0.08]		•
Heterogeneity: Tau ² =	0.00; Chi ² = 4	4.31, df = 1	1 (P < (0.00001); l ² = 1	75%				_	
Test for overall effect:				<i>n</i>						-0.2 -0.1 0 0.1 0.2 Higher in Controls Higher in Obesity
Test for subgroup diffe			1(P = 0)	0.67), $l^2 = 0\%$						Figher in Controls Figher in Obesity

Figure 10 Carotid IMT and obesity: analysis stratified by IMT measurement methodology. Forest plot of mean difference in carotid IMT between adults with obesity and healthy weight people stratified by IMT measurement methodology (manual or semi-automated/automated).






Figure 11 Funnel plot for obesity and brachial FMD.





in the primary search in order to minimize bias. Furthermore, a comprehensive search strategy was utilized that involved the use of both keyword and subject heading terms, US (Medline) and European (Embase) databases, and without application of language limits, thus searching for and reviewing both English and non-English articles. The sample size of research subjects (n = 12,554) is large, and sensitivity analyses were relatively consistent, suggesting that the findings are likely robust. Weaknesses and limitations of this work include the significant heterogeneity of results between studies. This may possibly relate to methodological differences in assessment of vascular health, for which there remains little standardization between laboratories. The different BMI cut-points and differences in prevalence of cardiometabolic risk factors may also have contributed to the heterogeneity. Furthermore, the majority of included studies are cross-sectional, and as such no causal relationship can be inferred. Only studies with data on obesity as defined by BMI, as widely used in clinical practice, were included. Although this facilitated comparison between studies, BMI lacks discriminatory power to differentiate between body fat and lean mass (21), as well as between subcutaneous and visceral obesity (22). Other measures of obesity, particularly those relating to regional distribution of adiposity, such as waist-hip ratio and waist circumference, in addition to direct measures of percentage body fat, may potentially be more closely linked to vascular health disturbances (23). Studies were excluded that treated BMI as a continuous variable. The findings are not able to inform



on the progression to endothelial dysfunction, changes in intima-media thickening over time or whether the effects of obesity on brachial FMD and carotid IMT are reversible. Not all studies presented data specifically for the different subgroups (age, gender, IMT measurement methodology), and as such the reported results are derived from a subset of studies, which may have reduced statistical power.

Whether the assessment of these markers of vascular health may have a role in the clinical management of obesity is unclear. The base-level equipment required is commonly available in the hospital setting, most notably B mode ultrasound with linear array transducer. Both techniques are routinely assessed in research, although they require a significant level of training to ensure reproducibility (24). Neither currently has a clearly defined role in clinical practice, although the use of these techniques to monitoring individual vascular responses to weight loss therapy as a potential means by which to identify strategies with the greatest likely cardiovascular benefit is an attractive concept that warrants further investigation (25).

In conclusion, these findings indicate that brachial FMD is lower and carotid IMT is greater in adults with obesity. Accordingly, changes in brachial FMD and carotid IMT may be important surrogate markers suitable for use in clinical trials of weight loss interventions. Furthermore, these findings provide a robust estimation of the effect sizes likely due to obesity, which will enable the effect sizes observed with weight loss interventions to be put into appropriate context.

Funding

J.Y.A.N was supported by a Sydney Medical School MBBS-MPhil scholarship. M.R.S is supported by a Future Leader fellowship from the National Heart Foundation of Australia (#100419).

Conflict of Interest Statement

M.R.S. received consultancy fees from AstraZeneca for his contribution to the development of educational resources relating to clinical management of type 2 diabetes. I.D.C. is a board member of the EXSCEL Trial Operations Committee. For this, he has received an honorarium. He has performed and still performs clinical trials of obesity treatment and prevention, some of which have been funded by the government and others by the pharmaceutical industry. Current trials are funded by the NHMRC (3), NovoNordisk, Pfizer, BMS and SFI. He has given talks for NovoNordisk, Servier Laboratories, Ache and Pfizer in the last 3 years. The Boden Institute of Obesity, Nutrition, Exercise and Eating Disorders (M.R.S., J.Y.A.N., I.D.C., C.M.Y.L.) currently receives or has grants pending, from Pfizer, NovoNordisk, Bristol-Myers Squibb, Egg Board and Soho Floridis International.

Author Contributions

J.Y.A.N. carried out the literature search, data collection, statistical analysis and drafted the manuscript; T.Y.C. independently screened articles; D.S.C. contributed to study conception; I.D.C. contributed to study conception; T.G. contributed to study conception; C.M.Y.L. assisted with statistical design and interpretation; M.R.S. contributed to study conception and interpretation of data. All authors were involved in writing the paper and had final approval of the submitted and published versions.

References

- Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al. Myocardial infarction and coronary deaths in the world health organization monica project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. *Circulation* 1994; **90**: 583–612.
- O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular health study collaborative research group. *N Engl J Med* 1999; **340**: 14–22.
- Fathi R, Haluska B, Isbel N, Short L, Marwick TH. The relative importance of vascular structure and function in predicting cardiovascular events. *J Am Coll Cardiol* 2004; 43: 616–623.
- Biasucci LM, Graziani F, Rizzello V, et al. Paradoxical preservation of vascular function in severe obesity. *Am J Med* 2010; **123**: 727–734.
- Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53: 1925–1932.
- Arcaro G, Zamboni M, Rossi L, et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. *Int J Obes Relat Metab Disord* 1999; 23: 936–942.
- Oflaz H, Ozbey N, Mantar F, et al. Determination of endothelial function and early atherosclerotic changes in healthy obese women. *Diabetes Nutr Metabol - Clin Exp* 2003; 16: 176–181.
- Joris PJ, Zeegers MP, Mensink RP. Weight loss improves fasting flow-mediated vasodilation in adults: a meta-analysis of intervention studies. *Atherosclerosis* 2015; 239: 21–30.
- Skilton MR, Yeo SQ, Ne JYA, et al. Weight loss and carotid intimamedia thickness – a meta-analysis. *Obesity* 2017; 25: 357–362.
- Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. *Int J Cardiovasc Imaging* 2010; 26: 631–640.
- Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness:

a systematic review and meta-analysis. *Circulation* 2007; **115**: 459–467.

- Aydin M, Bulur S, Alemdar R, et al. The impact of metabolic syndrome on carotid intima media thickness. *Eur Rev Med Pharmacol Sci* 2013; **17**: 2295–2301.
- Marini MA, Succurro E, Frontoni S, et al. Metabolically healthy but obese women have an intermediate cardiovascular risk profile between healthy nonobese women and obese insulin-resistant women. *Diabetes Care* 2007; **30**: 2145–2147.
- Zhu LY, Hu LY, Wang GY, Wang XH. Comparison of vascular endothelial function in simple obesity and metabolic syndrome patients. [Chinese]. *J Clin Rehabil Tissue Eng Res* 2007; 11: 2240–2242.
- Wilson PW, Bozeman SR, Burton TM, et al. Prediction of first events of coronary heart disease and stroke with consideration of adiposity. *Circulation* 2008; **118**: 124–130.
- Hashimoto M, Akishita M, Eto M, et al. The impairment of flow-mediated vasodilatation in obese men with visceral fat accumulation. *Int J Obes Relat Metab Disor: J Int Assoc Stud Obes* 1998; 22: 477–484.
- Yu RH, Ho SC, Ho SS, Woo JL, Ahuja AT. Association of general and abdominal obesities and metabolic syndrome with subclinical atherosclerosis in asymptomatic chinese postmenopausal women. *Menopause* 2008; 15: 185–192.
- Green DJ, Jones H, Thijssen D, Cable N, Atkinson G. Flow-mediated dilation and cardiovascular event prediction does nitric oxide matter? *Hypertension* 2011; 57: 363–369.
- Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the international brachial artery reactivity task force. *J Am Coll Cardiol* 2002; **39**: 257–265.
- Dolores Mauricio M, Aldasoro M, Ortega J, Vila JM. Endothelial dysfunction in morbid obesity. *Curr Pharm Des* 2013; **19**: 5718–5729.
- Prentice AM, Jebb SA. Beyond body mass index. Obes Rev 2001;
 141–147.
- Janssen I, Heymsfield SB, Allison DB, Kotler DP, Ross R. Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. *Am J Clin Nutr* 2002; **75**: 683–688.
- Ho SC, Chen YM, Woo JL, Leung SS, Lam TH, Janus ED. Association between simple anthropometric indices and cardiovascular risk factors. *Int J Obes Relat Metab Disor: J Int Assoc Stud Obes* 2001; 25: 1689–1697.
- Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness consensus (2004–2006). *Cerebrovasc Dis* 2007; 23: 75–80.
- Flammer AJ, Anderson T, Celermajer DS, et al. The assessment of endothelial function: From research into clinical practice. *Circulation* 2012; **126**: 753–767.
- Yu Y, Li H, Yu H, Wang C, Pu S. The relationship between insulin resistance and endothelium-dependent vasodilatation in obese subjects. *Zhonghua Yi Xue Za Zhi* 2003; **83**: 1467–1470.
- Pulerwitz T, Grahame-Clarke C, Rodriguez CJ, et al. Association of increased body mass index and impaired endothelial function among hispanic women. *Am J Cardiol* 2006; **97**: 68–70.
- Olson TP, Schmitz KH, Leon AS, Dengel DR. Vascular structure and function in women: relationship with body mass index. *Am J Prev Med* 2006; **30**: 487–492.

- Mizia-Stec K, Gasior Z, Zahorska-Markiewicz B, et al. The indexes of arterial structure and function in women with simple obesity: a preliminary study. *Heart Vessels* 2008; 23: 224–229.
- Patel AR, Hui H, Kuvin JT, Pandian NG, Karas RH. Modestly overweight women have vascular endothelial dysfunction. *Clin Cardiol* 2009; **32**: 269–273.
- Skilton MR, Sieveking DP, Harmer JA, et al. The effects of obesity and non-pharmacological weight loss on vascular and ventricular function and structure. *Diabetes Obes Metab* 2008; 10: 874–884.
- Lind L, Zethelius B, Sundbom M, Eden Engstrom B, Karlsson FA. Vasoreactivity is rapidly improved in obese subjects after gastric bypass surgery. *Int J Obes (Lond)* 2009; **33**: 1390–1395.
- Fahs CA, Smith DL, Horn GP, et al. Impact of excess body weight on arterial structure, function, and blood pressure in firefighters. *Am J Cardiol* 2009; **104**: 1441–1445.
- Ayer JG, Harmer JA, Steinbeck K, Celermajer DS. Postprandial vascular reactivity in obese and normal weight young adults. *Obesity* 2010; 18: 945–951.
- Zhu W, Zeng J, Yin J, et al. Both flow-mediated vasodilation procedures and acute exercise improve endothelial function in obese young men. *Eur J Appl Physiol* 2010; **108**: 727–732.
- Ayer JG, Harmer JA, David C, et al. Severe obesity is associated with impaired arterial smooth muscle function in young adults. *Obesity* 2011; **19**: 54–60.
- Mah E, Matos MD, Kawiecki D, et al. Vitamin c status is related to proinflammatory responses and impaired vascular endothelial function in healthy, college-aged lean and obese men. *J Am Diet Assoc* 2011; **111**: 737–743.
- Doupis J, Rahangdale S, Gnardellis C, et al. Effects of diabetes and obesity on vascular reactivity, inflammatory cytokines, and growth factors. *Obesity* 2011; 19: 729–735.
- Vinet A, Karpoff L, Walther G, et al. Vascular reactivity at rest and during exercise in middle-aged obese men: effects of short-term, low-intensity, exercise training. *Int J Obes (Lond)* 2011; 35: 820–828.
- Martin BJ, Verma S, Charbonneau F, et al. The relationship between anthropometric indexes of adiposity and vascular function in the fate cohort. *Obesity* 2013; **21**: 266–273.
- Karason K, Wikstrand J, Sjostrom L, Wendelhag I. Weight loss and progression of early atherosclerosis in the carotid artery: a four-year controlled study of obese subjects. *Int J Obes Relat Metab Disord* 1999; 23: 948–956.
- Ciccone M, Maiorano A, De Pergola G, et al. Microcirculatory damage of common carotid artery wall in obese and non obese subjects. *Clin Hemorheol Microcirc* 1998; **21**: 365–374.
- Mavri A, Stegnar M, Sentočnik JT, Videčnik V. Impact of weight reduction on early carotid atherosclerosis in obese premenopausal women. *Obes Res* 2001; **9**: 511–516.
- De Michele M, Panico S, Iannuzzi A, et al. Association of obesity and central fat distribution with carotid artery wall thickening in middle-aged women. *Stroke* 2002; **33**: 2923–2928.
- Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. *Arch Intern Med* 2008; **168**: 1609–1616.
- 46. Blaha MJ, Rivera JJ, Budoff MJ, et al. Association between obesity, high-sensitivity c-reactive protein ≥2 mg/l, and subclinical atherosclerosis: implications of jupiter from the multi-ethnic study of atherosclerosis. *Arterioscler Thromb Vasc Biol* 2011; **31**: 1430–1438.

© 2017 The Authors

Obesity Science & Practice published by John Wiley & Sons Ltd, World Obesity and The Obesity Society. Obesity Science & Practice

- Park J, Kim SH, Cho GY, et al. Obesity phenotype and cardiovascular changes. J Hypertens 2011; 29: 1765–1772.
- Csongradi E, Nagy B Jr, Fulop T, et al. Increased levels of platelet activation markers are positively associated with carotid wall thickness and other atherosclerotic risk factors in obese patients. *Thromb Haemost* 2011; **106**: 683–692.
- Ecemis GC, Kahraman H, Nural MS, Aslan HS, Atmaca A. The relationship between insulin resistance and carotid artery intimamedia thickness in obese and morbidly obese women. *Turk J Med Sci* 2012; **42**: 1121–1128.